

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Is the UK losing its position as a destination for world leading clinical research? A review of performance of haematological cancer clinical trials

Journal:	BMJ Open		
Manuscript ID	bmjopen-2024-086058		
Article Type:	Original research		
Date Submitted by the Author:	04-Mar-2024		
Complete List of Authors:	Arora, Meena; Onconova Therapeutics Inc, Kilcoyne, Adrian; Celularity Inc Bolodeoku, Dr; JB Consulting (MDP) Ltd, 1 Bell Street el Baghdady, Assem; King's College London		
Keywords:	Clinical Trial, Leukaemia < HAEMATOLOGY, Health Equity		





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Is the UK losing its position as a destination for world leading clinical research? A review of performance of haematological cancer clinical trials

Arora M (0009-0007-7608-457X), Kilcoyne A, Bolodeoku J (0000-0003-4261-9285), el Baghdady A (0009-0004-4673-5034)

AFFILIATIONS:

Meena Arora, Vice President, Global Medical Affairs and R&D, Onconova Therapeutics,

USA

Adrian Kilcoyne, Chief Medical Officer & Executive Vice President, Cellularity Inc., New

Jersey, USA

John Bolodeoku, Visiting Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Assem el Baghdady, Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Corresponding author

Meena Arora, Vice President, Global Medical Affairs and R&D, Onconova, USA meenakarora@icloud.com

Summary

What is already known on this subject

- Clinical trials are of critical importance to the UK.
- UK research is among the highest quality globally and has been evaluated in this study with a focus on haematological cancer trials against the USA and reference European countries France, Germany, Italy and Spain.
- Despite the UK providing quality research of clinical and economic importance, the proportion of global clinical trials conducted within the UK is declining.

What this study adds

Reduced share of global research, particularly Phase 2 clinical studies, risks a
potential loss of research leadership in the UK, which could have extensive
implications for patients' ability to access innovative therapies as well as material

economic consequences for the UK.

- Whilst the volume of clinical research may be declining in the UK, the quality of research being conducted in the UK remains high as does commitment to completion of studies being undertaken.
- This study demonstrated that outputs from UK clinical trials in the form of publication are of the highest value of all countries evaluated appearing in high impact journals with the highest citability indices.

to per teries only

ABSTRACT Objectives

 To understand the competitive position of the UK in comparison to Europe and USA for haematological cancer clinical research.

Design

Evaluate clinical trial numbers, their effectiveness and publication outputs using commercially available databases.

Primary outcome measures

Healthcare expenditure per capita, country comparisons of clinical study experience, implementation, effectiveness and publication.

Results

The UK spends least on clinical studies and spend per capita than comparator European countries, despite having comparable prevalence of disease. UK clinical trial numbers declined versus comparator countries, and clinical trial implementation overall was lowest versus other countries. The USA had the highest number of studies underway, with UK ranked fourth of five European countries, but clinical trial completion rates were relatively good ranking as the third highest performing country for Phase 2 and 3 studies. However, clinical trial effectiveness overall was poor for the UK compared with other European countries, with respect to applications, ethics approvals, median time to start up and rate of non-enrolling sites. UK trial initiation was ranked fourth out of the five European countries, only marginally faster than Spain and the UK had the highest proportion of sites that failed to enrol any patients (despite regulatory timings for the UK being comparable to Germany and France). Data dissemination following clinical trials in the UK however is robust and of high quality compared with other countries. The UK publishes high quality, diverse research with citation rates from clinical studies which is higher than every other country, including the USA who publish five-fold more publications per year.

Conclusion

Whilst research in the UK remains amongst the highest quality and value, the UK is losing its position globally as an attractive destination for executing clinical trials. Reversal of this decline is of critical importance for the UK economy and patient access to innovative cancer medicines.

Article summary

Strengths and limitations of this study

- The strengths of this study are the use of robust databases that give an accurate overview of clinical trial volumes in the UK and reference countries, breakdown of clinical trials by phase and data relating to enrolment.
- Limitations include the timing of data analyses which cannot explore data in the year up to and following the signing of the Brexit exit agreement at the end of 2021.
- Another limitation is the assumption that publication in the UK reflects the prestige of UK researchers and work undertaken in the UK, the impact of publication in the UK because of other factors was not evaluated.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

The authors declare there are no conflicts of interest.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

Clinical trials are critical to provide early access to life-saving medicines for patients, improve future standards of clinical care and inform future clinical practice that optimises patient outcomes.

Development of new therapies is expensive with costs ranging from \$765.9 million to \$2771.6 million depending on the indication. [1] Clinical trials by the pharmaceutical and biotech industries is essential to clinical development of new therapeutic options to advance patient outcomes and because of cost will continue to be relevant.

Industry sponsored clinical trials provide material economic benefits to healthcare through revenue generation and the provision of free access to medicines for patients. For example, in Italy, 92% of funding for clinical studies was derived from pharmaceutical industry, quantified with a worth of more than €750 million. [2] Similarly, two recent studies have suggested that for every euro invested by the pharmaceutical industry there is a net financial gain for the overall economy. [3, 4] Additional positive outcomes of clinical trials include employment of specialised medical and managerial personnel so that clinical trials provide an 'employment multiplier' of 1.66. [3]

Clinical trials enable clinicians to provide treatment within the trial setting without charge, and often subsidise care through free diagnostics and other treatments and provide funding for administrative and operational work. Additionally, it ensures that physicians remain at the cutting edge of scientific advances as they get first-hand experience in applying the newest scientific advances.

Clinical trials provide benefits to both clinicians and patients. For patients, trials provide access to innovative and potentially life-prolonging medications years in advance of regulatory approval and reimbursement. In areas such as oncology this remains an area of high unmet need. This unmet need is recognised by the UK Government. A recent UK Commons Cancer Services report April 2022 stated: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in National Health Service (NHS) cancer care." [5] For clinicians, involvement in clinical trials enables them to be at the forefront of medical research and improves understanding of present, and potential future, standards of care.

BMJ Open

The attractiveness for a country to implement and deliver clinical trials relies on a combination of factors including market size, regulatory timelines, costs of implementation and clinical trial outputs. Data from the Association of British Pharmaceutical Industry (ABPI) suggest that despite applications for clinical trials to the UK Medicines and Healthcare Regulatory Agency (MHRA) remaining stable, the number of industry sponsored studies has declined over the course of 2017–2020, reducing from 667 to 508, a decrease of 24%. [6]

Now that the UK has left the European Union, exploring the potential for it as a major player in clinical trials is essential. Brexit poses additional challenges to the UK in attracting clinical trial implementation including barriers to data sharing, the removal of regulatory mutual recognition, compatibility of regulatory and medicine research approaches, information access and health security. [7]

In this study to explore the attractiveness of a country for implementation of clinical trials programmes the following points were considered:

- country population
- expenditure on healthcare per capita
- prevalence of disease
- clinical trials experience
- clinical trial and ethics approval processes and timelines

However, understanding exclusively the number of clinical trials within a country is to ignore the scope and value of research being done. To address this an analysis of clinical trial performance and calibre of research by publication and patent applications was undertaken, to give an overall view of not only research volume but also its value. This is an imperative because whilst clinical trial volume may be of significant financial benefit to a healthcare economy, it is the scientific value that is important to progress new therapies for patients and improve outcomes.

The aim of this research was to explore and understand the attractiveness of the UK as a destination for running clinical trials compared to reference European countries and to understand requirements for change to ensure the UK can become and remain an essential and attractive country for clinical trial development and implementation. This research also compared European and UK data against that for the USA as high-income country with comparable healthcare standards. This research provides a snapshot of the UK's standing versus key European countries and the USA, using haematological cancer as an example, with respect to clinical trial development, implementation, and regulatory approval.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

METHODS

Countries across Europe were included in this study (France, Germany, Italy and Spain) as comparators for the UK. These countries were evaluated as all were considered high-income countries with comparable healthcare standards and economies, geography and socioeconomic factors. The USA was also included as a comparator high-income country with a robust approach to research, comparable to, but different from Europe.

Data to explore country wealth and healthcare expenditure, disease prevalence, clinical trial implementation and publication of clinical trial data were collated. Country economic data were established using data from the Organisation for Economic Co-operation and Development (OECD Paris, France). Data for disease epidemiology were provided from the Thomson Reuters' Incidence and Prevalence database (IPD, Clarivate Inc. Philadelphia, USA). To provide specific epidemiological data, the example of leukaemia as a haematological cancer was used across all countries evaluated. Clinical trial numbers and stage of development were evaluated using data extracted from Cortellis Clinical Trial Intelligence (extraction date September 2017) (Clarivate Inc. Philadelphia, USA). To analyse the number of completed haematological cancer studies within development Phases 1, 2 and 3 for each of the 6 countries, Clarivate Cortellis Clinical trial intelligence was searched. A modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) analysis approach was used to identify all studies that had been conducted within the haematological cancer disease area in each of the countries. To evaluate the value of clinical studies as well as volume, measures such as trial completion, published data and patent applications leading to possible useable drug entities were explored using Thomson Reuters Cortellis Regulatory Intelligence and Thomson Reuters Web of Science (both Clarivate Inc. Philadelphia, USA). Search parameters for publication searches were: "Leukemia" OR "Leukaemia" OR "Myeloma" OR "Myelodysplastic syndrome" OR "Myelodysplasia" OR "Myelofibrosis" OR "Myeloproliferative neoplasm" OR "Hematological malignan*" OR "Haematological malignan*" OR "Hematological cancer" OR "Haematological cancer" OR "Blood cancer" OR "Bone marrow cancer" OR "Plasma neoplasm" OR "Plasma cell neoplasm" OR "Plasmacytoma" OR "Liquid tumor" OR "Liquid tumour" OR "Hodgkin* " OR "Waldenstrom macroglobulinemia" OR "Reed-Sternberg cells" OR "Lymphoma" OR "B cell neoplasm" OR "T cell neoplasm" OR "Natural Killer cell neoplasm" OR "NK cell neoplasm" OR "Heavy chain disease" OR "Lymphomatoid granulomatosis".

Performance of clinical trials as a method to establish the attractiveness of a country for clinical trials was evaluated using data from the Centre for Medicine Research (CMR) (Clarivate Inc. Philadelphia, USA) and the metrics of trial start up, trial site recruitment rate and clinical trial site efficiency. Trial start-up was measured as median time from the end of the clinical trial application (CTA) approval process to enrolling the first patient. Recruitment rates were assessed by the number of patients enrolled per site per month. Evaluation of site efficiency was measured by the proportion of sites which were initiated to start trials but did not enrol any patients. Patents for clinical medicines in haematological cancers were analysed using Thomson Reuters Web of Science and Thomson Reuters Cortellis (including Derwent Would Patents Index) databases.

RESULTS

Analysis of countries studied

Country wealth and healthcare expenditure

Results from the macro development analysis indicated that population size and healthcare spend were not proportional. The highest population from OECD data were observed in the USA (313.1 million) and a GDP percentage spend of 7.9%. These data compare with Germany whose population at 82.1 million is a third of the USA but spends 8.4% of its GDP on healthcare. For both countries GDP growth rates were comparable (Figure 1). GDP spend on healthcare as a proportion of mean expenditure per capita was lowest in the UK at less than 5% (Figure 1). Data for Spain were not available from the OECD but indicated a GDP spend of 8.9% – the highest of all countries evaluated, and a population of 46.6 million.

Investment in healthcare suggested highest expenditure in the US with the UK and Italy the lowest investing countries per capita. (Figure 1). USA healthcare expenditure per capita was almost double that of the UK (\$4317 versus \$2532). The UK, Germany, France and Italy each contributed approximately 2% to global GDP (Spain contributed approximately 1.3%). GDP in France was \$3,533 billion, Germany \$5.011 billion, Italy £3,180 billion, Spain \$2,301 billion and the UK \$3,479 billion. Healthcare spending in Germany, France and Spain was comparable (range 8.6%–8.9% GDP). When mean expenditure on healthcare per capita was examined the UK ranked the lowest of all countries evaluated.

Figure 1. Proportion of GDP spend on healthcare and mean expenditure by capita across study countries

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. Data were not available for Spain when the search was conducted, and subsequently checked in 2022.

Disease prevalence across comparator countries

Prevalence of leukaemia across all countries in the study was broadly comparable (Table 2), ranging from 32.3/100,000 population in the UK to 45.6/100,000 population in France. As expected the USA, with a population size more than three times larger than the largest European country Germany, the estimated total patients with leukaemia was greater than 100,000. The UK had a projected leukaemia population equivalent to Italy and more than 9,000 patients fewer than both Germany and France.

Table 2: Prevalence of Leukaemia data by country and estimated number of total patients

Therapeutic area	Country	Prevalence (per 100,000 pop)	Estimated total patients
	USA	33.1	103,636
Llaamatalagiaal	UK	32.3	20,220
cancers*	France	45.6	29,093
	Germany	34.4	28,242
	Italy	34.3	20,820
	Spain	37.9	17,661

*To address data meaningfully, prevalence data were limited to leukaemia only. Leukaemia included acute lymphocytic leukaemia; chronic lymphocytic leukaemia; acute myeloid leukaemia; chronic myeloid leukaemia.

Evaluation of clinical studies across comparator countries

Implementation of clinical trials from Phase 1 healthy volunteer to Phase 3

registration trials

 Most haematological cancer trials were conducted in the USA (n=3,254) with the UK and Italy having the lowest number of trials (n=380 and 538, respectively) (Table 3). The distribution of these studies by country and phase is shown in Table 3 and demonstrated a predominance of Phase 1 healthy volunteer as well as Phase 1 and Phase 2 haematological cancer studies in the USA (Table 3). The UK conducted a comparable number of healthy volunteer and Phase 1 haematological cancer studies with other European countries (Table 3). Phase 2 clinical trials were the most commonly implemented trial phase in the UK but the

numbers of Phase 2 studies was lower than Germany, France and Italy who conducted the most Phase 2 haematological cancer studies outside of the US (Table 3).

The number of Phase 3 haematological cancer studies was broadly comparable across Europe (n=239–257) except for Spain who conducted only 171 Phase 3 studies. The UK conducted 240 Phase 3 studies, and ranked third among European countries suggesting that the UK performs well with respect to this phase of study. (Table 3) As expected, European figures were considerably lower than the number of Phase 3 studies conducted in the USA (n=402) (Table 3).

The number of active haematological cancer trials underway was evaluated for comparison with the number of registered studies. In 2017 the number of active haematological cancer clinical studies was lowest in both the UK and Spain (n=177 and 141, respectively) compared with all other countries (Figure 2). The UK lagged considerably behind Germany, Italy and France, despite having a comparable population size and mean healthcare expenditure spend to Italy.

Country	Total number of haematological clinical trials (2017)	Healthy volunteers (2017)	Haematological cancer studies by Phase (2017)		
		Phase 1	Phase 1 Haematological cancer	Phase 2	Phase 3
USA	3,254	1,241	1,352	2,735	402
France	643	73	104	359	247
Germany	665	57	72	378	257
Italy	538	31	48	371	239
Spain	632	33	45 🛀	192	171
UK	380	74	88	282	240

Table 3. Number of clinical studies by Phase conducted across analysed countries.

Figure 2. Number of active haematological cancer trials in study countries

Clinical trial volumes were evaluated through exploration of the number of clinical trials completed by phase and country (Figure 3). These data suggest that whilst clinical trial volume in the UK may be low in comparison to other European countries, once initiated clinical trials in the UK are likely to be completed. For Phase 2 and 3 studies, the UK was

third of all comparator countries completing more studies behind only the USA and Germany, and for Phase 1 studies the UK was the highest European country completing studies with only the USA completing more.

Not surprisingly, the number of clinical trials completed in the USA are comparable to the sum of all European countries considered in this study. The USA had the highest rate for trial completion across all phases and Spain and Italy the lowest. With respect to trial completion across Phases 1–2 the USA trial completion counts were at least 2-fold greater than any individual European country included in the analysis (USA n=728; Germany n=396; UK n=306; France n=245; Spain n=225; Italy n=226). Study completion by Phase for USA was 4-fold higher for Phase 1. For Phase 3 clinical studies USA rates of trial completion were higher but less pronounced than overall data (30–50% higher than European countries). By comparison, for Phase 3 clinical studies the USA completed approximately 27% more studies than Germany, the highest-ranking European country. In Phases 2 and 3 the UK was the second highest completing country in Europe outside of Germany.

Figure 3. Documented completion of clinical trials by phase by country

Analysis of clinical trial effectiveness

Clinical trial implementation

Clinical trial implementation and completion provide an insight into research across comparator countries but do not provide insight into the potential impact and effectiveness of clinical trials and their outcomes in those countries. A review of clinical trial application and ethics' approval times were demonstrably shortest in the USA (Figure 4; Table 5) for national review and approval. Spain and Italy had the longest processes at 60 days for CTA approval and 60 days for ethics approval. For the UK ethics' approval times were a 30-day maximum and CTA approval maximum of 60 days. Evaluation of clinical trial effectiveness across countries is shown in Table 4 demonstrating that Germany was the fastest European country being two-fold faster than the slowest European country, Spain. The UK was only marginally faster than Spain with a median of 186 days from approval to trial start up. The UK also had the highest rate of non-enrolling clinical trial sites at 27.9%, an attrition rate that was comparable with Germany (Table 4), but almost twice that of the USA and four times higher than Italy. Across all countries median enrolment rate per site over time was broadly comparable.

	Country	Median start up duration (Days)	Median enrolment rate (Patients /site / month)	Proportion of non-enrolling sites (%)
	USA	111	0.5	15.9
	UK	186	0.4	27.9
Haematological	France	141	0.6	18.7
cancers	Germany	92	0.6	25.9
	Italy	122	0.5	6.5
	Spain	195	0.6	16.2

Figure 4. Maximum expected approval times for clinical trial applications and ethics approvals

Table 5. Timings for ethics approval for clinical trial and approval times for clinical
trial applications

	Maximum expected site ethics approval (days)	Maximum expected time to CTA approval (days)	Total maximum review time to clinical trial approval (days)
France	35	60	95
Germany	60	30	90
Italy	60	60	120
Spain	60	60	120
UK	60	30	90
USA		30	30

Analysis of clinical trial outcomes

Research impact analysis

To explore the impact of clinical trial research across the studied countries the volume and impact of clinical trial derived data was evaluated. Turning research implementation into outputs as measured through publications, citations and patents was highest in the USA, followed by Germany, with Spain lagging (Table 6). Whilst total publication number was similar between Italy and UK (11,143 and 10,579, respectively) citations derived from UK published research was the highest of all countries evaluated (Table 6).

With respect to calibre of research publication diversity the UK was a smaller entity for clinical trials, but research was published in high calibre, highly cited journals ranking third of all countries evaluated, including the USA. Similarly, the number of patent applications arising from UK-sited clinical trials was high, ranked third of all countries evaluated and the second highest European country (Table 6). Evaluation of research diversity of research in the UK with respect to haematological cancers derived from keyword representation suggested the UK has a broad diversity of research and was the only country where there was a predominance of publications in childhood leukaemia, a trend not reflected elsewhere.

Table 6. Research output by country 2012–2017 as evaluated from publications and patents.

Total To number of nu publications of au	tal Total mber number of thors citation	Number of citations per s publication (n)	Proportion of publications in high Impact	Number of patent applications related to
---	--	---	---	---

					Factor journals (%)	clinical trials
USA	51,574	92,064	533,973	10.4	8.3	6,888
UK	10,579	14,920	125,172	11.8	7.5	729
France	9,132	15,091	101,283	11.1	7.4	525
Germany	13,580	19,163	129,984	9.8	5.9	1,037
Italy	11,143	18,741	97,554	8.8	5.0	311
Spain	5,361	10,162	57,388	10.7	6.5	166

to beet teriew only

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

DISCUSSION

Clinical research has the potential to advance science and revolutionise outcomes for patients. There are economic, healthcare and societal benefits to the UK being part of this milieu. However, clinical trials require investment in terms of time, finance and researcher training, which is outweighed by the potential gains both to patients and society.

Clinical trial performance

Our research suggests that whilst the UK in 2017 was performing relatively well compared with the rest of Europe, with some greater expertise in Phase 1 and Phase 2 studies, it is losing ground. Overall, the UK conducted fewest haematological clinical trials, ranking fourth out of five European countries for Phase 2 studies although better rankings were observed for both Phase 3 and Phase 1 studies. A review of active haematological clinical trials in the UK similarly suggested a low performance against European comparator countries despite having similar disease prevalence and healthcare expenditure to higher performing countries like Germany. However, for ongoing haematological cancer trials as of 2017, the UK lagged behind almost all European countries, bar Spain.

Patient population sizes were between 17,661 in Spain and 29,093 in Germany, but when pooled across Europe were broadly comparable with that in the USA (116,036 versus 103,636). The USA conducted almost six times as many haematological cancer clinical trials compared to the UK, a trend that was replicated across clinical studies overall. In this study the number of clinical trials in the USA was not adjusted for population and so clinical trial volume was predominantly a function of population size, and explains why the USA, with fivefold larger population, ranks first. With such access to patients and a comparable prevalence of leukaemia to the UK and other European countries their ability to engage with eligible patients outranks individual countries in Europe. Evaluation of trial completions shows that the USA consistently ranked highest in terms of completion and therefore experience. These data are unsurprising given its much larger population compared to each individual European country included in the study and reflects trends in clinical trials overall. [8]

The highest trial completion in Europe was seen in Germany, perhaps reflecting their high levels of experience of running clinical trials as defined by this analysis. For the UK and France, the picture was a little more variable. The UK had a high rate of study completion for Phase 1 clinical studies specifically, perhaps reflective of the UK's experience in this area. Importantly, if the proportion of completed haematological cancer trials against the number

 BMJ Open

of active trials was evaluated it was apparent that whilst numerically the UK may have implemented fewer clinical trials it does drive them through to completion; third behind the USA and Germany for Phase 2 and Phase 3 studies and second only to the USA for Phase 1 studies.,

Clinical trial effectiveness

An overview of clinical trial efficiency using proportional data provided a different perspective. As shown in Table 4, Italy, a less populated country, was most efficient in clinical trial start up, recruitment and enrolment, with the USA second and the UK fifth ahead of Spain. Data suggest that the UK has lost some impetus in initiating and driving clinical trials with long start-up times to initiate studies which will have consequences for the UK economic and for patient access to innovative medication.

Approval time is a key factor in determining the attractiveness of a country for clinical trial roll out. Typically, in any country a CTA needs to be reviewed by a number of organisations in addition to central and local ethics committee reviews. Depending on the specific country, review processes may be sequential or in parallel, with each review having an expected maximum duration. From the various country specific processes, it was possible to calculate a maximum expected review time for a CTA. In the UK, authorisation from the MHRA is mandatory to conduct a clinical trial alongside favourable opinions from relevant Ethics Committees. Applications to the Ethics Committee and the MHRA may proceed in parallel or sequentially, depending on the wishes of the sponsor organisation. By comparison, in Spain, it is necessary to obtain a favourable opinion of the corresponding Clinical Research Ethics Committee (CREC/EC), the agreement from the management of the centre where the study is to be conducted and the authorisation of ethics committees and the Spanish Agency of Medicines and Medical Devices (AEMPS) may or may not proceed in parallel, but the process is often enacted sequentially. It is interesting to note that with respect to clinical trial implementation the UK was ranked low, typically fifth of the six countries evaluated. At 186 days, UK authorisation took twice as long as Germany and was a third longer than the USA.

The UK is uniquely placed for clinical trial implementation by merit of the National Health Service (NHS) whose infrastructure can provide a well characterised patient population for studies, combined with world class medical capability. However, as a largely Trust-based decentralised system any advantages are cancelled and this may explain the UK rankings among other European countries. Clinical trial providers often need to undergo lengthy negotiation with the NHS before a trial can be set up, resulting in higher trial costs per

patient than other European countries and a mitigation of any advantages a shortened maximum time to ethical approval might give a trial sponsor. Furthermore, patient inclusion in oncology trials in the UK is largely voluntary compared with the USA where inclusion is often mandatory. In Germany the number of patent applications in 2017 was more than 1,000 with 30% fewer applications lodged in the UK in the same period. It is tempting to speculate that Germany's desire to innovate drives patent applications and their high standing for clinical trial volume and completion. However, with the UK and Germany having comparable times to ethics and CTA approval and the UK having only 30% fewer patent applications Germany's innovation alone is insufficient to explain the disparity between Germany and the UK.

Contrasting volume against quality as a metric for attractiveness

Volume analysis alone, however, provides only a limited perspective. Understanding the value and reach of clinical trial outcomes is of equal importance and is vital to progress therapies for future approval and use in patient. Analysis of research output and quality demonstrated that clinical data derived in the UK are widely published and widely accepted as shown by citation rates and of excellent quality. The UK's demonstrable drive to publish data ranked it second in Europe behind Germany and third when the USA is included. Consideration of publication citations which were highest in the UK infer that research in the UK is robust, relevant and interesting and it is tempting to translate this inference as a surrogate marker that the UK is a deliverer or high-quality research.

Positioning the UK as an attractive clinical trial partner

For the UK to be a go-to destination for clinical trial research, other drivers besides research quality need to be understood, for example clinical trial activity. From a European perspective Germany remains the country with the most experience in orchestrating Phase 2 and 3 clinical trials. This analysis cannot intimate reasons for Germany's excellence in clinical trial implementation, but possible explanations include a large haemato-oncology patient population as well as good trial infrastructure and high post-trial market potential. Similarly, the regulatory environment in Germany via the Arzneimittelmarkt-Neuordnungsgesetz (Pharmaceuticals Market Reorganisation Act [AMNOG]) procedure encourages collaboration on research to help support pricing of drugs.

Given the excellence in early Phase clinical trials in the UK, there is a need to explore how improvements in later Phase clinical trials can be achieved. Phase 3 clinical trials are the point where patients can directly access and benefit from medications for their cancer.

BMJ Open

Options that might be considered to improve the proportion of Phase 3 studies undertaken in the UK include shortening of regulatory timeframes and financial competitive advantages. The UK was shown to be the slowest at 186 days for the regulatory process, which will impact the consideration of the UK as a country of interest. Optimising this timeframe needs to be considered, likely at a governmental level, to bring approvals in line with other countries such as Germany and the US, particularly in a post-Brexit era where access to the centralised approvals system through the European Medicines Agency (EMA) is no longer available. Similarly, there is a need to streamline CTA and ethics procedures. This process is underway through collaboration of the Medical Health Regulatory Agency (MHRA) with the National Institute for Health Research (NIHR) to combine procedures of Clinical Trials of Investigational Medical Products and Clinical Trial Authorisation and Research Ethics Committee opinion. Such a combined way of working may improve approval times. Delays in trial startups are linked to substantial study delays and costs which can threaten the feasibility of a trial, delay access to treatment for patients and lead to lost opportunity costs. [9, 10] But, this may require digital transformation and support of digital capabilities, as it is clear that biopharma excellence and digital excellence may not track together. [11] With a median trial set up time for the UK of 6 months, double that of Germany, success of this initiative is a priority. There is a case for central incentivisation of clinical trials in the UK, as happens in the US, that is strategically applied to centres of excellence providing innovation. [12] Embracing the increasing patient centricity of clinical trials may provide the UK with a competitive advantage in clinical trial design and recruitment without compromising on time to trial implementation.

Reinvigorating the clinical trial landscape in the UK – particularly following Brexit, the pandemic and an economic downturn – is essential for the fiscal benefits it brings and the benefits to patients in accessing innovative medications. The NHS as a national structure provides multiple centres of excellence and Clinical Research Networks that are highly respected worldwide. However, the NHS continues to operate under increasing burdens, including insufficient funding, patient waiting lists, staff shortages, an aging population and evolving healthcare needs. As such, the system remains at capacity with the capability to undertake research seriously compromised.

However, both the UK and Europe lag behind the USA in terms of clinical trial investment and countries such as China are increasingly emerging as attractive locations for studies. [12] A connected, less siloed, approach to clinical trial implementation within the UK alone and within the broader context of Europe is required.

Limitations

There are several limitations to these data. From observed data it has been inferred that the UK may be a less attractive country for clinical trials than others in Europe, however nuances to this observation have not been evaluated. It may be that a subjective analysis of pharmaceutical companies and clinical research organisations, perhaps by survey, might provide a different or deeper insight into why the UK up to 2017 was seemingly a more difficult country to navigate for late phase clinical studies. The outcomes we observed suggested that perhaps regulatory hurdles were proving to be barriers to later phase clinical trials, but the impact of a centralised approval structure in the UK has not been evaluated. It may be that current constraints faced by the NHS may, in part, render clinical development in the UK less attractive. This would be an interesting topic for further study. It is possible that limitations of infrastructure may be a contributing factor to the high number of sites recruited for clinical studies which never recruit patients. The data in this study provide insight into haematological cancer clinical trials up to and including 2017. Consequently, the impact of Brexit and the COVID-19 pandemic are not reflected. It would be useful to explore the impact of the UK of both these events since this research. Whilst the data obtained reflect the situation in the UK up to, and including 2017, the situation in the UK, post-Brexit and post-pandemic cannot be known. Other limitations not explored in this analysis include cost of developing and implementing clinical trials in the UK and other countries, and the potential for Governmental incentives to improve attractiveness. Understanding the role of geographical location for clinical trials requires an analysis of willingness of countries to invest in clinical studies, their landscape of current healthcare funding, clinical trial capacity from the perspective of the potential patient population and the willingness of patients to be involved in research and would be of interest for future study.

Conclusions

Based on 2017 data the UK lags other European countries as a hub for clinical trial development and implementation. The UK however, when it does undertake clinical trials, clearly provides data that are meaningful and relevant and ultimately useful to drug development and future patient care. As the post-pandemic landscape shifts in the UK, it may be that future data would show an increase in the volume and impact of clinical development in the UK. Since the pandemic the UK Government is proposing to improve the UK as a clinical trials hub. Its response has been to explore the role of telemedicine in trials, the definition of a 'trial' site, and to revise ways of working in line with recommendations from

 the Taskforce for Innovation, Growth and Regulatory Reform (TIGRR) including ICH E6 guidance on good clinical practice and the development of an Innovative Licensing and Access Pathway (ILAP). In this way effective and efficient pathways to bring innovative medicines to patients earlier should be possible with the UK as a hub for clinical trials. [13]

Acknowledgements

Writing assistance and editorial support was provided by Dr Susan Allen, Brandfish Limited UK. The views of the authors are those solely of the authors and may not reflect the view of their employers or companies.

Author contributions

All authors were responsible for developing and critiquing the survey, data collation and data preparation. All authors were responsible for data analysis and interpretation. All authors equally contributed to the conception and outline of the manuscript. All authors critically reviewed each draft and equally contributed to the revisions. All authors reviewed and approved the final manuscript for submission.

Data sharing

All data are available upon reasonable request to the corresponding author.

Consent for publication

All authors agree to the publication of this manuscript.

References

- 1. Wouters, O.J., M. McKee, and J. Luyten, *Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.* J Am Med Assoc, 2020. **323**(9): p. 844–853.
- 2. Polignano, M.G., et al., *Economic impact of industry-sponsored clinical trials in inflammatory bowel diseases: Results from the national institute of gastroenterology "Saverio de Bellis"*. Frontiers in Pharmacology, 2022. **13**.
- 3. Walter, E., et al., *Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.* J Med Econ, 2020. **23**(6): p. 566–574.
- 4. Tran, D.T., et al., *The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.* Journal of Pharmacy & Pharmaceutical Sciences, 2018. **20**(1): p. 407–414.
- 5. UK Government, House of Commons Health and Social Care Committee. *Cancer Services, Twelfth Report of Session 2021–22.* 2022. Available from:

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2	
2	
1	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
<u>_</u> 2∆	
27	
25	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
20	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
 10	
40	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	
59	

60

1

https://committees.parliament.uk/publications/9562/documents/161967/default/
accessed January 2024.
Association of Pritich Dharmasoutical Industrias (ADDI) Clinical research in the

- Association of British Pharmaceutical Industries (ABPI). *Clinical research in the UK, an opportunity for growth*. 2021. Available from: <u>https://www.abpi.org.uk/publications/clinical-research-in-the-uk-an-opportunity-for-growth/</u> accessed January 2024.
- 7. Medicines and Healthcare Products Regulatory Agency (MedRegs). *The past, the present and the future of clinical trials transparency in the UK.* 2021. Available from: <u>https://medregs.blog.gov.uk/2021/12/22/the-past-the-present-and-the-future-of-clinical-trials-transparency-in-the-uk/</u> accessed January 2024.
- 8. World Health Organisation (WHO). *Number of clinical trial registration by location, disease, phase of development, age and sex of trial participants (1999–2021)*. 2021. Available from: <u>https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development</u> accessed January 2024.
- 9. Atassi, N., et al., *Analysis of start-up, retention, and adherence in ALS clinical trials.* Neurology, 2013. **81**(15): p. 1350–5.
- 10. Kantarjian, H., D.J. Stewart, and L. Zwelling, *Cancer research in the United States:* Dying by a thousand paper cuts. Cancer, 2013. **119**(21): p. 3742–3745.
- 11. IMD World Digital Competitiveness Centre. *World digital competitiveness ranking* 2022. 2022. Available from: <u>https://www.imd.org/centers/world-competitiveness-center/rankings/world-digital-competitiveness/</u> accessed January 2024.
- 12. European Federation of Pharmaceutical Industries and Associations (EFPIA). Factors affecting the location of bipharmaceutical investments and implications for European policy priorities. 2022. Available from: <u>https://www.efpia.eu/media/676753/cra-efpia-investment-location-final-report.pdf</u> accessed January 2024.
- Medicines and Healthcare Regulatory Agency (MHRA) Inspectorate. *Regulators'* experience of clinical trials during the COVID-19 pandemic (Part 3) – looking forward. 2022. Available from: <u>https://mhrainspectorate.blog.gov.uk/2022/02/18/regulators-</u> <u>experience-of-clinical-trials-during-the-covid-19-pandemic-part-3-looking-forward/</u> accessed January 2024.

Fig 1



	Population	GDP per	Annual GDP	GDP spent	Mean
	(Million)	capita	projected	on	expenditure
		(US\$ per	growth rate (%)	healthcare	per capita
		capita)		(%)	(US \$)
USA	313.1	54,640	2.8	7.9	4,317
UK	62.6	32,225	2.3	7.3	2,352
France	63.8	38,870	1.7	8.6	3,343
Germany	82.1	44,985	2.3	8.4	3,779
Italy	60.7	35,067	1.5	6.8	2,385
Spain	46.6	33,720	2.8	8.9*	3,001*

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. *Data was not available for Spain when the search was conducted, and subsequently checked in 2022.





Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Fig 4





Is the UK losing its position as a destination for world leading clinical research? A comparative analysis of haematological cancer clinical trials performance

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-086058.R1
Article Type:	Original research
Date Submitted by the Author:	16-Aug-2024
Complete List of Authors:	Arora, Meena; Onconova Therapeutics Inc, Kilcoyne, Adrian; Celularity Inc Bolodeoku, Dr; JB Consulting (MDP) Ltd, 1 Bell Street el Baghdady, Assem; King's College London
Primary Subject Heading :	Public health
Secondary Subject Heading:	Oncology, Health policy
Keywords:	Leukaemia < HAEMATOLOGY, Health Equity, Clinical Decision-Making





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Is the UK losing its position as a destination for world leading clinical research? A comparative analysis of haematological cancer clinical trials performance

Arora M (0009-0007-7608-457X), Kilcoyne A (0009-0002-7882-8927), Bolodeoku J (0000-0003-4261-9285), el Baghdady A (0009-0004-4673-5034)

AFFILIATIONS:

 Meena Arora, Vice President, Global Medical Affairs and R&D, Onconova, USA; Visiting

Lecturer, King's College London, UK

Adrian Kilcoyne, Chief Medical Officer & Executive Vice President, Cellularity Inc., New

Jersey, USA

John Bolodeoku Visiting Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Assem el Baghdady Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Corresponding author

Meena Arora, meenakarora@icloud.com

Summary

What is already known on this subject

- Clinical trials are of critical importance to the UK.
- UK research is among the highest quality globally and has been evaluated in this study with a focus on haematological cancer trials against the USA and reference European countries France, Germany, Italy and Spain.
- Despite the UK providing quality research of clinical and economic importance, the proportion of global clinical trials conducted within the UK is declining.

What this study adds

• Reduced share of global research, particularly Phase 2 clinical studies, risks a potential loss of research leadership in the UK, which could have extensive

 implications for patient's ability to access innovative therapies as well as material economic consequences for the UK.

- Whilst volume of clinical research may be declining in the UK, the quality of research being conducted in the UK remains high as does commitment to completion of studies being undertaken.
- This study demonstrated that outputs from UK clinical trials in the form of publication are of the highest value of all countries evaluated appearing in high impact journals with the highest citability indices.

or occition in the second

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

ABSTRACT Objectives

To understand the competitive position of the UK in comparison to Europe and USA for haematological cancer clinical research.

Design

Using commercially available databases, clinical trial numbers, their effectiveness and publication outputs were evaluated in two analyses: a macro development and a research activity and performance analysis.

Data sources

The following databases were used for this analysis: Organization for Economic Cooperation and Development (OECD), Thomson Reuters Incidence and Prevalence, the Cortellis Clinical Trial Intelligence, the Clarivate Cortellis Innography Patent Intelligence, Thomson-Reuters Cortellis Regulatory Intelligence, Thomson Reuters Web of Science and data from the Centre for Medicine Research (CMR).

Eligibility criteria

Countries of Europe with comparable geographic, healthcare standards and economies and the USA as the largest country where research is undertaken. All haematological oncology clinical trials from Phase 1 to Phase 3 were included.

Data extraction and synthesis

All data were retrieved in September 2017 and macroeconomic data were reviewed in 2022; haematological cancer data were restricted to leukaemias generally as a surrogate reference for haematological oncology indications; research output publication data were evaluated using specific MeSH search terms between 2010–2017. Key metrics explored included healthcare expenditure per capita, study experience across countries, comparative capability of each country for clinical trial implementation, clinical trials' performance and impact of research as measured by impact factor and citation metrics of publications.

Results

Revenue for clinical studies is lower in the UK than comparable European countries. All studied countries had comparable leukaemia prevalence rates, but the UK spent least per capita on healthcare versus France, Germany, Spain and USA. The number of clinical studies in the UK showed a decline compared with other European countries. Clinical trial

implementation was lowest in the UK (n=380) versus Germany (n=665), France (n=643), Spain (n=632), Italy (n=538), and the USA (n=3,254). Registered versus active clinical studies suggested the USA had the highest number underway (n=824), with UK ranked fourth of five European countries (Germany=239, Italy=232, France=211, UK=177 and Spain=141). However, the UK had the highest completion rate of Phase 3 studies it did initiate (n=154, 87%) and performance was comparable with Germany (n=188, 78.7%) and France (n=151, 71.6%). When analysed by Phase, the UK was the second highest European performing country (n=121) for Phase 2 study completion compared with Germany (n=182) both less than the USA (n=345). The UK completed the most Phase 1 studies compared with other European countries, only second to the USA (n=31 versus n=126). However, the UK clinical trial performance metrics were negatively impacted for the UK compared in comparison other European countries with respect to clinical trial application process, timelines, ethics committee approvals, median time to start up and rate of non-enrolling sites. The UK was slower to initiate studies (median 186 days) versus 92 for Germany, 141 France, 122 Italy, only marginally faster than Spain (195 days). Whilst median enrolment rates were comparable across all countries, the UK had the highest proportion of sites that failed to enrol any patients (despite regulatory timings for the UK being comparable to Germany [90 days] and France [95 days]). Publication of data following clinical trials in the UK however is robust and of the highest quality compared with other countries, judged by journal placement and publication citations. The UK publishes high quality, diverse research with citation rates (11.8) from clinical studies which is higher than every other country, including the USA who publish five-fold more publications per year.

Conclusion

Whilst research in the UK remains amongst the highest quality and value globally, the UK may be losing its position globally as an attractive destination for executing clinical trials. This may be trend that is recognised by the UK Government, but it is vital to reverse the trend of clinical trial decline and to improve the UK's economic outlook for the UK, and patient early access to innovative cancer medicines.

Article summary

Strengths and limitations of this study

- The strengths of this study are the use of robust commercial databases that give an accurate overview of clinical trial volumes in the UK and reference countries, breakdown of clinical trials by phase and data relating to enrolment.
- Limitations include the timing of data analyses which cannot explore data in the years up to and following the signing of the Brexit exit agreement at the end of 2021 and is explored in ongoing research.
- Another limitation is the assumption that publication in the UK reflects the prestige of UK researchers and work undertaken in the UK, the impact of publication in the UK because of other factors was not evaluated.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Competing interests

The authors declare there are no current conflicts of interest. MA, JB and AK were employees of Celgene during the time the analysis was conducted. The analysis was conducted as part of research for a successfully defended MSc thesis for MA, which was funded by Celgene and Amryt Pharmaceuticals.

INTRODUCTION

Clinical trials are critical to provide early access to life saving medicines for patients, improve future standards of clinical care and inform future clinical practice that optimises patient outcomes.

Development of new therapies is expensive with costs estimated from \$765.9 million to \$2771.6 million depending on the indication. [1] Clinical trials by the pharmaceutical and biotech industries are an essential part of the clinical trial mix which include industry and academic sponsored studies to support clinical development of new therapeutic options to advance patient outcomes. Cost and complexity of development of novel molecules and clinical trial infrastructure means that industry and academic collaboration in clinical trials is critical.

Industry sponsored clinical trials provide material economic benefits to healthcare in the UK through revenue generation. Clinical trials, regardless of their funding, also provide opportunities for patients to access novel medicines and resources for the duration of the trial and maybe beyond into long-term extension phases. In Italy, 92% of funding for clinical studies was derived from pharmaceutical industry, quantified with a worth of more than €750 million. [2] It was further suggested that industry sponsored clinical trials also further benefit country healthcare system in terms of avoided costs, whereby patients enrolled into clinical trials reduce financial burden on healthcare systems for the duration of the clinical trial. [3] Two recent studies have suggested that for every Euro invested by the pharmaceutical industry there is a net financial gain for the overall economy of at least 25%. [4,5] A study in Austria suggested additional positive outcomes of clinical trials including employment of specialised staff including researchers, medical and managerial personnel so that clinical trials provide an 'employment multiplier' of 1.66, [4] a benefit that may also be realised in other geographies where clinical trials are carried out.

Clinical trials enable clinicians to provide treatment within the trial setting without charge, and often subsidise care through free diagnostics and other treatments and provide funding for administrative and operational work. Additionally, it ensures that physicians remain at the cutting edge of scientific advances as they get first-hand experience in applying the newest scientific advances.

Clinical trials provide benefits to both clinicians and patients. For patients, trials provide access to innovative and potentially life prolonging medications years in advance of
regulatory approval and reimbursement. And for clinicians, clinical trials enable participation in cutting edge medical research that can improve and shape current and future standards of care. However, for patients it must be noted that access to innovative, experimental treatments is not risk free, and participation in such trials runs a risk of experiencing adverse events, possible toxicity or lack of drug effectiveness.

In areas such as oncology this remains an area of high unmet need. This unmet need is recognised by the UK Government. A recent UK Commons Cancer Services report April 2022 stated: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in National Health Service (NHS) cancer care." [6] The outcome for patients relies on a complex interchange between available infrastructure, access to therapies and standard of care. It is difficult to fully understand and was not evaluated if poorer patient outcomes in the UK was due to lower opportunities to participate in clinical trials, but it is an important part of the treatment journey that warrants further investigation. Clinical trials do provide an avenue for patients to access novel medications so it follows any impact on clinical trial start up, implementation, and delivery may impact patient access and maybe outcome although this is likely to be minor compared with issues such as size of waiting lists that can impact cancer pathways for patients in the UK.

The attractiveness for a country to implement and deliver clinical trials relies on a combination of factors including market size, regulatory timelines, costs of implementation and clinical trial outputs. Data from the Association of British Pharmaceutical Industry (ABPI) suggest that despite applications for clinical trials to the UK Medicines and Healthcare Regulatory Agency (MHRA) remaining stable, the number of industry sponsored studies has declined over the course of 2017–2020, reducing from 667 to 508, a decrease of 24%. [7]

Now that the UK has left the European Union, exploring the potential for the UK as a major player in clinical trials is essential. Brexit poses additional challenges to the UK in attracting clinical trial implementation including barriers to data sharing, the removal of regulatory mutual recognition, compatibility of regulatory and medicine research approaches, information access and health security. [8]

In this analysis to explore the attractiveness of a country for implementation of clinical trials programmes the following points were considered:

- country population
- expenditure on healthcare per capita
- prevalence of disease
- clinical trials experience
- clinical trial and ethics approval processes and timelines

However, understanding exclusively the number of clinical trials within a country is to ignore the scope and value of research being done. To address this an analysis of clinical trial performance and calibre of research by publication and patent applications was undertaken, to give an overall view of not only research volume but also its value. This is an imperative because whilst clinical trial volume may be of significant financial benefit to a healthcare economy, it is the scientific value that is important to progress new therapies for patients and improve outcomes.

The aim of this research was to explore and understand the attractiveness of the UK as a destination for running clinical trials compared to reference European countries and to understand requirements for change to ensure the UK can become and remain an essential and attractive country for clinical trial development and implementation. This research also compared European and UK data against that for the USA as high-income country with comparable healthcare standards. This research provides a snapshot of the UK's standing versus key European countries and the USA, using haematological cancer as an example, with respect to clinical trial development, implementation, and regulatory approval.

METHODS

Countries across Europe were included in this study (France, Germany, Italy and Spain) as comparators for the UK. These countries were evaluated as all were considered high-income countries with comparable healthcare standards and economies, geography and socioeconomic factors. The USA was also included as a comparator high-income country with a robust approach to research, comparable to, but different from Europe.

Data to explore country wealth and healthcare expenditure, disease prevalence, clinical trial implementation and publication of clinical trial data were collated. Country economic data were established using data from the Organisation for Economic Co-operation and Development (OECD Paris, France), and whilst healthcare spend cannot always provide insight into the quality of healthcare delivery, countries were chosen for their approximate comparability. Data for disease epidemiology was provided from the Thomson Reuters' Incidence and Prevalence database (IPD, Clarivate Inc. Philadelphia, USA). The IPD covers

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

over 4,500 diseases, procedures, symptoms and other health issues for incidence, prevalence, morbidity, mortality, comorbidity, treatment or diagnosis rates and cost. The IPD tracks and reports the epidemiological content from more than 280 medical journals and over 35 government and industry agencies. It is updated every 4 weeks and so is an efficient single source to access current data. Limitations of the databases used meant it was not possible to evaluate specific haematological cancers (Leukaemia, Multiple Myeloma, Relapsed Refractory Myeloma, Non- Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Follicular Lymphoma, CNS Lymphoma) and so leukaemia was adopted as a surrogate for all haematological cancer subtypes across the countries studied. Clinical trial numbers and stage of development were evaluated using data extracted from Cortellis Clinical Trial Intelligence (extraction date September 2017) (Clarivate Inc. Philadelphia, USA). To analyse the number of completed haematological cancer studies within development Phases 1, 2 and 3 for each of the 6 countries, Clarivate Cortellis Clinical Trial Intelligence was searched. A modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) analysis approach was used to identify all studies that had been conducted within the haematological cancer disease area in each of the countries. The Cortellis Clinical Trial Intelligence database is a single source of fully searchable and indexed global clinical trial content for more than 400,000 clinical trials evaluating drugs, drug-like entities, treatment/prophylactic medical devices, biomarkers, biologics, and vaccines. Data is populated daily from thousands of global sources, including more than 25 international clinical trial registries (including ClinicalTrials.gov, EudraCT, ISRCTN, JapicCTI etc), press releases, literature articles and conference reports.

To evaluate the value of clinical studies as well as volume, measures such as trial completion, published data and patent applications leading to possible useable drug entities were explored using Thomson Reuters Cortellis Regulatory Intelligence and Thomson Reuters Web of Science (both Clarivate Inc. Philadelphia, USA). The Thomson Reuters Cortellis Regulatory Intelligence, is a single, comprehensive source for global regulatory information and contains more than 143,000 current and historical documents from over 200 regulatory sources covering more than 70 countries. Data relating to the clinical trial application (CTA) and the site ethics submission process and estimated duration was extracted from Cortellis Regulatory Intelligence for each of the 6 countries.

MeSH search terms for both American and British English were used. Parameters for publication searches were: *"Leukemia"* OR *"Leukaemia"* OR *"Myeloma"* OR

"Myelodysplastic syndrome" OR "Myelodysplasia" OR "Myelofibrosis" OR "Myeloproliferative neoplasm" OR "Hematological malignan*" OR "Haematological malignan*" OR "Hematological cancer" OR "Haematological cancer" OR "Blood cancer" OR "Bone marrow cancer" OR "Plasma neoplasm" OR "Plasma cell neoplasm" OR "Plasmacytoma" OR "Liquid tumor" OR "Liquid tumour" OR "Hodgkin* " OR "Waldenstrom macroglobulinemia" OR "Reed-Sternberg cells" OR "Lymphoma" OR "B cell neoplasm" OR "T cell neoplasm" OR "Natural Killer cell neoplasm" OR "NK cell neoplasm" OR "Heavy chain disease" OR "Lymphomatoid granulomatosis".

Performance of clinical trials as a method to establish the attractiveness of a country for clinical trials was evaluated using data from the Centre for Medicine Research (CMR) (Clarivate Inc. Philadelphia, USA) and the metrics of trial start up, trial site recruitment rate and clinical trial site efficiency. The CMR database contains biopharmaceutical company sourced and validated performance metrics for over 400,000 sites and over 25,000 sponsorled, investigational drugs trials and is considered a gold standard for clinical performance metrics across the pharmaceutical industry. Trial start-up was measured as median time from the end of the clinical trial application (CTA) approval process to enrolling the first patient. Recruitment rates were assessed by the number of patients enrolled per site per month. Evaluation of site efficiency was measured by the proportion of sites which were initiated to start trials but did not enrol any patients. Patents for clinical medicines in haematological cancers were analysed using Thomson Reuters Web of Science (WoS) and Thomson Reuters Cortellis (including Derwent Would Patents Index) databases. These databases were selected as they contain multidisciplinary content covering 12,000 of highest impact journals and 150,000 conference proceeding papers, as well as data on product pipelines sourced from press release, company reports, industry deal report and conference abstracts.

No ethics approval was required for this analysis.

Patient and public involvement

No patient or public involvement was required in this analysis.

RESULTS

Analysis of countries studied Country wealth and healthcare expenditure

Results from the macro development analysis indicated that population size and healthcare spend were not proportional. The highest population from OECD data was observed in the USA (313.1 million) and a GDP percentage spend of 7.9%. These data compare with Germany whose population at 82.1 million is a third of the USA but spends 8.4% of its GDP on healthcare. For both countries GDP growth rates were comparable (Figure 1). GDP spend on healthcare as a proportion of mean expenditure per capita was lowest in the UK at less than 5% (Figure 1). Data for Spain was not available from the OECD but indicated a GDP spend of 8.9% – the highest of all countries evaluated, and a population of 46.6 million.

Investment in healthcare suggested highest expenditure in the US with the UK and Italy the lowest investing countries per capita. (Figure 1). USA healthcare expenditure per capita was almost double that of the UK (\$4317 versus \$2532). Comparison of GDP per country and the contribution to global GDP was noted as: France GDP \$3,533 billion of which 2% was contributed globally; Germany GDP \$5,011 billion of which 2% was contributed to global wealth; Italy GDP £3,180 billion of which 2% was contributed to global GDP was some contributed to global GDP and the UK whose GDP \$3,479 billion with a 2% global contribution. Healthcare spending in Germany, France and Spain was comparable (range 8.6%–8.9% GDP). When mean expenditure on healthcare per capita was examined the UK ranked the lowest of all countries evaluated (Figure 1).

Disease prevalence across comparator countries

Prevalence of leukaemia across all countries in the study was broadly comparable (Table 1), ranging from 32.3/100,000 population in the UK to 45.6/100,000 population in France. As expected, the USA, with a population size more than three times larger than the largest European country Germany, the estimated total patients with leukaemia was greater than 100,000. The UK had a projected leukaemia population equivalent to Italy and more than 9,000 patients fewer than both Germany and France.

Table 1: Prevalence	of Leukaemia*	data by	country	and	estimated	number	of	total
patients								

Therapeutic area	Country	Prevalence (per 100,000 pop)	Estimated total patients
Haematological cancers*	USA	33.1	103,636
	UK	32.3	20,220
	France	45.6	29,093
	Germany	34.4	28,242
	Italy	34.3	20,820
	Spain	37.9	17,661

 *To address data meaningfully, prevalence data was limited to leukaemia only. Leukaemia included acute lymphocytic leukaemia; chronic lymphocytic leukaemia; acute myeloid leukaemia.

Evaluation of clinical studies across comparator countries

Implementation of clinical trials from Phase 1 to Phase 3 registration trials

The number of active haematological cancer trials underway was evaluated for comparison with the number of registered studies. In 2017 the number of active haematological cancer clinical studies was lowest in both the UK and Spain (n=177 and 141, respectively) compared with all other countries (Figure 2a). The UK lagged considerably behind Germany, Italy and France, despite having a comparable population size and mean healthcare expenditure spend to Italy.

Most haematological cancer trials were conducted in the USA (n=3,254) with the UK and Italy having the lowest number of trials (n=380 and 538, respectively) (Figure 2b). The distribution of these studies by country and phase is shown in Figure 2 and demonstrated a predominance of Phase 1 and Phase 2 haematological cancer studies in the USA (Figure 2c). The UK conducted a comparable number of Phase 1 haematological cancer studies with other European countries (Figure 2b). Phase 2 clinical trials were the most commonly implemented trial phase in the UK but the numbers of Phase 2 studies was lower than Germany, France and Italy who conducted the most Phase 2 haematological cancer studies outside of the US (Figure 2b).

The number of Phase 3 haematological cancer studies was broadly comparable across Europe (n=239–257) except for Spain who conducted only 171 Phase 3 studies. The UK conducted 240 Phase 3 studies and ranked third among European countries suggesting that the UK performs well with respect to this phase of study. (Figure 2b) As expected, European figures were considerably lower than the number of Phase 3 studies conducted in the USA (n=402) (Figure 2b).

Clinical trial volumes were evaluated through exploration of the number of clinical trials completed by phase and country (Figure 2c). These data suggest that whilst clinical trial volume in the UK may be low in comparison to other European countries, once initiated clinical trials in the UK are very likely to be completed. For Phase 2 and 3 studies, the UK was third of all comparator countries completing more studies behind only the USA and Germany, and for Phase 1 studies the UK was the highest European country completing studies with only the USA completing more.

Not surprisingly, the number of clinical trials completed in the USA was comparable to the sum of all European countries considered in this study. The USA had the highest rate for trial completion across all phases and Spain and Italy the lowest. With respect to trial completion across Phases 1–2 the USA trial completion counts were at least 2-fold greater than any individual European country included in the analysis (USA n=728; Germany n=396; UK n=306; France n=245; Spain n=225; Italy n=226). Study completion by Phase for USA was 4-fold higher for Phase 1. For Phase 3 clinical studies USA rates of trial completion were higher but less pronounced than overall data (30–50% higher than European countries). By comparison, for Phase 3 clinical studies the USA completed approximately 27% more studies than Germany, the highest-ranking European country. In Phases 2 and 3 the UK was the second highest completing country in Europe outside of Germany.

Analysis of clinical trial effectiveness

Clinical trial implementation

Clinical trial implementation and completion provide an insight into research across comparator countries but do not provide insight into the potential impact and effectiveness of clinical trials and their outcomes in those countries. A review of clinical trial application and ethics' approval times were demonstrably shortest in the USA (Figure 3a) for national review and approval. Spain and Italy had the longest processes at 60 days for CTA approval and 60 days for ethics approval. For the UK ethics' approval times were a 30-day maximum and CTA approval maximum of 60 days and this was the same as that for Germany (Figure 3a,b).

Evaluation of clinical trial effectiveness across countries is shown in 3a,b demonstrating that Germany was the fastest European country in clinical trial start up being two-fold faster than the slowest European country, Spain. The UK was only marginally faster than Spain with a median of 186 days from approval to trial start up. The UK also had the highest rate of non-enrolling clinical trial sites at 27.9%, an attrition rate that was comparable with Germany (Figure 3b), but almost twice that of the USA and four times higher than Italy. Across all countries median enrolment rate per site over time was broadly comparable.

Analysis of clinical trial outcomes

Research impact analysis

To explore the impact of clinical trial research across the studied countries the volume and impact of clinical trial derived data was evaluated. Turning research implementation into outputs as measured through publications, citations and patents was highest in the USA,

followed by Germany, with Spain lagging (Table 2). Whilst total publication number was similar between Italy and UK (11,143 and 10,579, respectively) citations derived from UK published research was the highest of all countries evaluated (Table 2).

With respect to calibre of research publication diversity the UK was a smaller entity for clinical trials, but research was published in high calibre, highly cited journals ranking third of all countries evaluated, including the USA. Similarly, the number of patent applications arising from UK-sited clinical trials was high, ranked third of all countries evaluated and the second highest European country (Table 2). Evaluation of research diversity of research in the UK with respect to haematological cancers derived from keyword representation suggested the UK has a broad diversity of research and was the only country where there was a predominance of publications in childhood leukaemia, a trend not reflected elsewhere.

Table 2. Research output by country 2012–2017 as evaluated from publications and patents.

	Total number of publications	Total number of authors	Total number of citations	Number of citations per publication (n)	Proportion of publications in high Impact Factor journals (%)	Number of patent applications related to clinical trials
USA	51,574	92,064	533,973	10.4	8.3	6,888
UK	10,579	14,920	125,172	11.8	7.5	729
France	9,132	15,091	101,283	11.1	7.4	525
Germany	13,580	19,163	129,984	9.8	5.9	1,037
Italy	11,143	18,741	97,554	8.8	5.0	311
Spain	5,361	10,162	57,388	10.7	6.5	166
				-	1	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

DISCUSSION

Clinical research has the potential to advance science and revolutionise outcomes for patients. There are economic, healthcare and societal benefits for the UK being part of this milieu. However, clinical trials require investment in terms of time, finance and researcher training, which is outweighed by the potential benefits both to patients and society.

Clinical trial implementation

In this analysis the maximum expected time to achieve a CTA for each country was calculated. From this it was clear that the UK and Germany have the fastest approval times for CTAs and ethics approvals. Slower time in other countries such as Spain (120 days vs 90 days for UK) reflects the sequential nature of process of a favourable opinion from the Clinical Research Ethics Committee (CREC/EC), the agreement from the management of the centre where the study is to be conducted and the authorization of ethics committees and the Spanish Agency of Medicines and Medical Devices (AEMPS). By contrast approval times in the USA were the shortest, but our data does not reflect any inter-state differences that may arise.

However, with respect to clinical trial start up the UK in 2017 was slow compared with Germany. The difficulties in starting clinical trials in the UK has been noted and Governmental interventions have been implemented to reverse this trend in the post-COVID era including an increase in funding and removal of capital investment taxes for medicinal development in 2023 and the policy paper of the future of clinical research implementation plan 2022–2025 published in 2022.[9] There are glimmers of hope that these initiatives are showing promise. However, with a new Government in place in the UK, it will be imperative that the strides made to keep the UK competitive within clinical trial implementation and delivery is maintained and enhanced.

Clinical trial performance

Our research suggests that whilst the UK in 2017 was performing relatively well compared with the rest of Europe, with some greater expertise in Phase 1 and Phase 2 studies, it is losing ground. Overall, the UK conducted fewest haematological clinical trials, ranking fourth out of five European countries for Phase 2 studies although better rankings were observed for both Phase 3 and Phase 1 studies. Whilst it must be noted that differences between countries were not substantial when ongoing studies were evaluated, the UK overall was ranked fourth out of five, with only Spain conducting fewer studies in the year of investigation. This is despite the UK having similar disease prevalence and more broadly

BMJ Open

healthcare expenditure to higher performing countries like Germany. Healthcare spend per capita may not be translatable to delivery of high-guality healthcare, but when GDP percentage values for healthcare are also juxtaposed with ongoing haematological cancer trials as of 2017, the UK lagged behind almost all European countries, bar Spain, despite comparable prevalence data across all countries studied. We have conducted a second study exploring clinical study implementation over time, currently unpublished, which suggests that clinical trial numbers in the UK declined after 2017 to near 2011 levels, which is an effect not seen in comparator countries. Whilst this companion study represents the pre-COVID-19 environment a recent report has indicated that clinical trials initiated by industry has reduced by 15% to 4,900 trials in 2023 compared with 2022 and more than 32% lower than the peak in 2021, which was driven by COVID-19 trials. [10,11] The authors of this report suggested a potential driver of this decline was historic delay in trials startup or completion and that clinical trial starts in oncology, metabolic/endocrinology, immunology and neurology together were reduced by approximately 8%. [10,11] Our data gives a snapshot of haematological oncology trials which is consistent with other published reports in other areas of clinical research such as the IQVIA report published in 2024. [11]

One element that cannot be evaluated from the database results is the sponsor of clinical trials evaluated whether academic or industry sponsored. Recent data suggests that sponsorship of clinical trials by academic sources is robust with up to 62% of clinical trials sponsored in this way. [12] Academic sponsored studies encompass a wide range of study types from investigation of novel medicines or techniques to evaluation of real-world clinical practice, whilst industry sponsored study most often focuses on the investigation of novel medicines in new therapeutic areas. However, publication of results from academic clinical trials lags behind that of industry sponsored studies, likely due to reasons of restricted financial or personal capacity or academic priorities.[13] Either way, limiting publication of data risks an overall publication bias in available data, rectification of which would benefit patients and researchers alike and demonstrate a continued need for a diverse clinical trial landscape.

In oncology specifically, a review of trials from 2012–2017 indicated that 71% of trials were industry funded. [14] In the UK, the ABPI report indicated a decline from 2012 in clinical trials in the UK [7], a position supported by Cancer Research UK. As we have seen Governmental interventions have been devised and implemented to reverse this trend but fledgling programmes such as this will need time, investment and Governmental commitment to ensure they thrive.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Patient population sizes were between 17,661 in Spain and 29,093 in Germany, but when pooled across Europe were broadly comparable with that in the USA (116,036 versus 103,636). The USA conducted almost six times as many haematological cancer clinical trials compared to the UK, a trend that was replicated across clinical studies overall. In this study the number of clinical trials in the USA was not adjusted for population and so clinical trial volume was predominantly a function of population size, and explains why the USA, with fivefold larger population, ranks first. With such access to patients and a comparable prevalence of leukaemia to the UK and other European countries their ability to engage with eligible patients outranks individual countries in Europe. Evaluation of trial completions shows that the USA consistently ranked highest in terms of completion and therefore experience. These data are unsurprising given its much larger population compared to each individual European country included in the study and reflects trends in clinical trials overall [15]

The highest trial completion in Europe was seen in Germany, perhaps reflecting their high levels of experience of running clinical trials as defined by this analysis. For the UK and France, the picture was a little more variable. The UK had a high rate of study completion for Phase 1 clinical studies specifically, perhaps reflective of the UK's experience in this area. Importantly, if the proportion of completed haematological cancer trials against the number of active trials was evaluated it was apparent that whilst numerically the UK may have implemented fewer clinical trials it does drive them through to completion; third behind the USA and Germany for Phase 2 and Phase 3 studies and second only to the USA for Phase 1 studies. These data suggest that clinical trial research in the UK may be hindered numerically, but clinical trials started in the UK are typically completed and published with high impact and highly cited published data.

Clinical trial effectiveness

An overview of clinical trial efficiency using proportional data provided a different perspective. As shown in Figure 3, Italy, a less populated country, was most efficient in clinical trial start up, recruitment and enrolment, with the USA second and the UK fifth ahead of Spain. Data suggest that the UK has lost some impetus in initiating and driving clinical trials with long start-up times to initiate studies which will have consequences for the UK economic and for patient access to innovative medication. This trend, it is hoped, will be halted and reversed.

Approval time is a key factor in determining the attractiveness of a country for clinical trial roll out. Typically, in any country a CTA needs to be reviewed by a number of organisations in addition to central and local ethics committee reviews. Depending on the specific country, review processes may be sequential or in parallel, with each review having an expected maximum duration. From the various country specific processes, it was possible to calculate a maximum expected review time for a CTA. In the UK, authorisation from the MHRA is mandatory to conduct a clinical trial alongside favourable opinions from relevant Ethics Committees. Applications to the Ethics Committee and the MHRA may proceed in parallel or sequentially, depending on the wishes of the sponsor organisation. By comparison, in Spain, it is necessary to obtain a favourable opinion of the corresponding Clinical Research Ethics Committee (CREC/EC), the agreement from the management of the centre where the study is to be conducted and the authorisation of ethics committees and the Spanish Agency of Medicines and Medical Devices (AEMPS) may or may not proceed in parallel, but the process is often enacted sequentially. By contrast, it is interesting to note that with respect to clinical trial implementation the UK was ranked low, typically fifth of the six countries evaluated. At 186 days, UK authorisation took twice as long as Germany and was a third longer than the USA.

The UK is uniquely placed for clinical trial implementation by merit of the National Health Service (NHS) whose infrastructure can provide a well characterised patient population for studies, combined with world class medical capability. However, as a largely Trust-based decentralised system any advantages may be diminished, and this may explain the UK rankings among other European countries. Clinical trial providers often need to undergo lengthy negotiation with the NHS before a trial can be set up, resulting in slower start up times to enrolment, higher trial costs per patient than other European countries and a mitigation of any advantages a shortened maximum time to ethical approval might give a trial sponsor. However, it is hoped that initiatives underway to improve clinical trial implementation in the UK may soon reap benefits for the UK economy and patients.

This analysis could not evaluate how many trials undertaken in the studied countries led to licensed, regulatory approved and available medications accessible to patients. However, the number of patents related to clinical trials can be surmised to be a surrogate marker for molecules that are considered promising. In Germany the number of patent applications in 2017 was more than 1,000 with 30% fewer applications lodged in the UK in the same period (n=729). This places the UK only second in Europe behind Germany which suggests that the patent environment in the UK is quite attractive. However, given that the UK is 30% behind

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Germany it is tempting to speculate that Germany has more innovation driving patent applications and their high standing for clinical trial volume and completion or have compensatory mechanisms in place which make it an attractive location to lodge a patent. However, with the UK and Germany having comparable times to ethics and CTA approval and the UK having only 30% fewer patent applications Germany's innovation alone is insufficient to explain the disparity between Germany and the UK. Going forward, it would be interesting to explore in a future study, how Governmental intervention, the settling of the economic landscape post-Brexit and the renewed investment in clinical trials that have resulted following COVID-19 change the landscape for clinical trials and patent applications in the UK. The changing Governmental landscape in the UK may benefit these improvements further with increased investment or political willing and it will be interesting to evaluate the combined impact of these factors in the future. Within Europe the Accelerating Clinical Trials (ACT) programme [16] is similarly purported to transform the EU clinical trials landscape and so the impact of this on the UK, as a non-EU member is as yet unknown, and this warrants further investigation.

Contrasting volume against quality as a metric for attractiveness

Volume analysis alone, however, provides only a limited perspective. Understanding the value and reach of clinical trial outcomes is of equal importance and is vital to progress therapies for future approval and use in patient. Analysis of research output and quality was used as a surrogate marker of clinical trial performance. In the UK, it was noted that clinical trials when completed were typically published in high ranking, highly citable journals. Such wide publication of UK-led data in reputable journals demonstrates that clinical data derived in the UK is widely accepted by the academic and clinical community as being of high quality. The UK's demonstratable drive to publish data ranked it second in Europe in terms of publication volume behind Germany and third when the USA is included. However, the UK ranks first in Europe with respect to number of citations per publication and only second behind Germany for total citations. Consideration of publication citations which were highest in the UK infer that research in the UK is robust, relevant and interesting and we would translate this inference as a surrogate marker that the UK is a deliverer of high-quality research. Empirically, it might be assumed that there will be substantial lag between the end of a clinical trials, regardless of its phase and publication in a highly reputable journal. Whilst this may be true in some instances and is believed anecdotally, data evaluating the time lag between the end of Phase 2 and Phase 3 studies suggests this is not the case with a study evaluating clinical trial study publications in the BMJ, JAMA, Lancet and NEJM indicating a median time from trial completion to publication of only 431 days (Range 278-618) which was not statistically different for positive or negative results.[17,18] Time-lags in data

BMJ Open

dissemination however, when they do arise can be acknowledged to impede knowledge diffusion, and in the case of novel medicines may impact time to regulatory approval and reimbursement which may require published data for their evaluation. However, it is anticipated that the publication data presented here from 2017 whilst it might reflect clinical data completed in the previous year or two, remains a robust marker of high-quality data dissemination, and we would anticipate that this has continued over time regardless of any changes to the clinical trial landscape in the UK.

Positioning the UK as an attractive clinical trial partner

The UK has demonstrated instances where academic clinical trial infrastructure can align to deliver effective, timely and impactful results. Examples of this include the RECOVERY trial evaluating approved drugs in the management of COVID-19 and the STAMPEDE trial exploring the role of radiotherapy in prostate cancer. Whilst COVID-19 was a once in a generation event, promoting a highly favourable landscape for clinical research, it shows that the UK can deliver clinical trial excellence that leads the world, particularly for the evaluation of approved therapies. However, for the UK to be a go-to destination for clinical trial research for pre-approved or investigational molecules, other drivers besides research quality need to be understood, for example clinical trial activity. Our results show that in terms of Phase 3 clinical trial activity the UK is comparable to Italy, but lags Germany and France, a gap that is wider when Phase 2 trials are considered. From a European perspective Germany remains the country with numerically the most experience in orchestrating Phase 2 and 3 clinical trials – a total of 635 trials compared with the UK at 522 trials. This analysis cannot intimate reasons for Germany's excellence in clinical trial implementation but given that the ethical frameworks for Germany and the UK are comparable, possible explanations include a large haemato-oncology patient population as well as good trial infrastructure leading to fast start up of clinical trials and high post-trial market potential. Similarly, the regulatory environment in Germany via the Arzneimittelmarkt-Neuordnungsgesetz (Pharmaceuticals Market Reorganisation Act [AMNOG]) procedure encourages collaboration on research to help support pricing of drugs.

The UK demonstrates through this analysis that clinical trials when started are more likely to be completed and when completed to translate into highly robust publications and patent applications. In Phase 1 studies, the UK is leader across the board, and in haematological cancers only second to France. Given the excellence in early Phase clinical trials in the UK, there is a need to explore how improvements in later Phase 2 and 3 clinical trials can be achieved to increase the number of trials undertaken that can be completed and translated

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

into strong citable communicable data that sets the UK apart as a place for researchers, academic trial funding and pharma opportunity. Phase 3 clinical trials are the point where patients can directly access and benefit from medications for their cancer. Options that might be considered to improve the proportion of Phase 3 studies undertaken in the UK include shortening of regulatory timeframes and financial competitive advantages. The UK was shown to be the slowest at 186 days for the regulatory process, which will impact the consideration of the UK as a country of interest. Optimising this timeframe needs to be considered, likely at a governmental level, to bring approvals in line with other countries such as Germany and the US, particularly in a post-Brexit era where access to the centralised approvals system through the European Medicines Agency (EMA) is no longer available. Similarly, there is a need to streamline CTA and ethics procedures. This process is underway through collaboration of the Medical Health Regulatory Agency (MHRA) with the National Institute for Health Research (NIHR) to combine procedures of Clinical Trials of Investigational Medical Products and Clinical Trial Authorisation and Research Ethics Committee opinion. This will comprise the largest overhaul of trial regulation for several decades and accompanies a UK Government commitment to increase clinical trial investment from approximately £9 billion in 2017 the timing of this analysis to £22 billion by 2026–2027. Such a combined way of working may improve approval times. Delays in trial startups are linked to substantial study delays and costs which can threaten the feasibility of a trial, delay access to treatment for patients and lead to lost opportunity costs. [19,20] But, this may require digital transformation and support of digital capabilities, as it is clear that biopharma excellence and digital excellence may not track together. [21] With a median trial set up time for the UK of 6 months, double that of Germany, success of this initiative is a priority. There is a case for central incentivisation of clinical trials in the UK, as happens in the US, that is strategically applied to centres of excellence providing innovation. [22] The joint MHRA and NIHR approach may already be providing benefits with a reduction in clinical trial start up times already reported. Embracing the increasing patient centricity of clinical trials through use of the NHS may provide the UK with a competitive advantage in clinical trial design and recruitment without compromising on time to trial implementation.

Re-invigorating the clinical trial landscape in the UK – particularly following Brexit, the pandemic and an economic downturn – is essential for the fiscal benefits it brings and the benefits to patients in accessing innovative medications. The NHS as a national structure provides multiple centres of excellence and Clinical Research Networks that are highly respected worldwide. However, the NHS continues to operate under increasing burdens, including insufficient funding, patient waiting lists, staff shortages, an aging population and

BMJ Open

However, both the UK and Europe lag the USA in terms of clinical trial investment and countries such as China are increasingly emerging as attractive locations for studies. [22] A connected, less siloed, approach to clinical trial implementation within the UK alone and within the broader context of Europe is required.

Limitations

There are several limitations to these data. From observed data it has been inferred that the UK may be a less attractive country for clinical trials than others in Europe, however nuances to this observation have not been evaluated. It may be that a subjective analysis of pharmaceutical companies and clinical research organisations, perhaps by survey, might provide a different or deeper insight into why the UK up to 2017 was seemingly a more difficult country to navigate for late phase clinical studies. The outcomes we observed suggested that perhaps regulatory hurdles were proving to be barriers to later phase clinical trials, but the impact of a centralised approval structure in the UK has not been evaluated. It may be that current constraints faced by the NHS may, in part, render clinical development in the UK less attractive. This would be an interesting topic for further study. It is possible that limitations of infrastructure may be a contributing factor to the high number of sites recruited for clinical studies which never recruit patients.

The data in this study provide insight into haematological cancer clinical trials up to and including 2017. The data cut-off of 2017 is a challenge; however, these data do allow us to fully understand the UK's capability without the significant uncertainty of the Brexit vote and subsequent COVID-19 pandemic. It would be useful to explore the impact of the UK of both these events since this research. Whilst the data obtained reflects the situation in the UK up to, and including 2017, the situation in the UK, post-Brexit and post-pandemic cannot be known. Given the lifecycle of clinical trials is approximately 10 years, it would be interesting to explore the UK's position with respect to clinical trials in 2027 or beyond. At this timepoint the landscape should reflect a normalcy following Brexit, be relieved of any masking of effect by the COVID-19 pandemic and reflect more clearly the Government initiatives currently in place, which are beginning to provide benefits which we hope will be continued by the new UK Government. Other limitations not explored in this analysis include cost of developing and implementing clinical trials in the UK and other countries, and the potential for Governmental incentives to improve attractiveness. Understanding the role of geographical

location for clinical trials requires an analysis of willingness of countries to invest in clinical studies, their landscape of current healthcare funding, clinical trial capacity from the perspective of the potential patient population and the willingness of patients to be involved in research and would be of interest for future study.

Conclusions

Based on 2017 data the UK lags other European countries as a hub for clinical trial development and implementation. The UK however, when it does undertake clinical trials, clearly provides data that are meaningful and relevant and ultimately useful to drug development and future patient care. As the post-Brexit, post-pandemic landscape shifts in the UK, it may be that future data would show an increase in the volume and impact of clinical development in the UK. Since the pandemic the UK Government proposed to improve the UK as a clinical trials hub. Its response has been to explore the role of telemedicine in trials, the definition of a 'trial' site, and to revise ways of working in line with recommendations from the Taskforce for Innovation, Growth and Regulatory Reform (TIGRR) including ICH E6 guidance on good clinical practice and the development of an Innovative Licensing and Access Pathway (ILAP). In this way effective and efficient pathways to bring innovative medicines to patients earlier should be possible with the UK as a hub for clinical trials. [23]

Acknowledgements

Writing assistance and editorial support was provided by Susan Allen, Brandfish Limited UK and funded by Amryt Pharmaceuticals. The analysis was conducted as part of a successfully defended and awarded MSc thesis from King's College London, by MA funded by Celgene and Amryt Pharmaceuticals.

Authors' contributions

Meena Arora (MA) is the guarantor

MA was responsible for developing and critiquing the survey, data collation and data preparation, data analysis and interpretation, developing the concept and outline of the manuscript and writing, reviewing and revising the manuscript.

JB was responsible for critiquing the survey, data interpretation, developing writing, reviewing and revising the manuscript.

AeB was responsible for critiquing the survey, data interpretation, developing writing,

reviewing and revising the manuscript.

AK JB was responsible for critiquing the survey, data interpretation, developing writing,

reviewing and revising the manuscript.

Consent for publication

All authors agree to the publication of this manuscript.

Ethics Approval Not applicable

Figure 1. overview and proportion of GDP spend on healthcare by capita across study countries

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. Data was not available for Spain when the search was conducted, and subsequently checked in 2022.

Figure 2. a) number of active haematological cancer trials in study countries; b) documented number of clinical trials by phase by country; c) completion of clinical trials by phase by country

Figure 3. a) clinical trial performance metrics by countries evaluated; b) maximum expected approval times for clinical trial applications and ethics approvals

References

- 1. Wouters, O.J., M. McKee, and J. Luyten, *Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.* J Am Med Assoc, 2020. **323**(9): p. 844–853.
- 2. FADOI. *The value of independent clinical research in Italy.* Edra Roche Foundation 2019. Available from: <u>https://www.fondazioneroche.it/</u> accessed July 2024
- 3. Polignano M.G., *Economic impact of industry-sponsored clinical trials in inflammatory bowel disease: results from th enational institute of gastroenterology "Saverio de Bellis".* Front Pharmacol, 2022; **13**: 1027760.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1	
2	
3	
4	
5	
6	
0	
7	
8	
9	
1	Λ
1	0
1	1
1	2
1	3
1	- Л
1	-
1	5
1	6
1	7
1	8
1	0
-	9
2	0
2	1
2	2
2	2
2	<u>с</u>
2	4
2	5
2	6
2	7
2	/ ^
2	8
2	9
3	0
2	1
2	י ר
3	2
3	3
3	4
З	5
2	۵ ۵
3	0
3	7
3	8
3	9
1	0
4	0
4	1
4	2
4	3
1	Δ
4	4
4	5
4	6
4	7
Δ	Q
-	0
4	9
5	0
5	1
5	2
F	- 2
5	د
5	4
5	5
5	6
5	7
ر -	/ c
5	8
5	9
~	^

- 4. Walter, E., et al., *Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.* J Med Econ, 2020. **23**(6): p. 566–574.
 - 5. Tran, D.T., et al., *The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.* Journal of Pharmacy & Pharmaceutical Sciences, 2018. **20**(1): p. 407–414.
 - 6. UK Government, House of Commons Health and Social Care Committee. *Cancer Services, Twelfth Report of Session 2021–22.* 2022. Available from: <u>https://committees.parliament.uk/publications/9562/documents/161967/default/</u> accessed January 2024.
 - Association of British Pharmaceutical Industries (ABPI). Clinical research in the UK, an opportunity for growth. 2021. Available from: <u>https://www.abpi.org.uk/publications/clinical-research-in-the-uk-an-opportunity-for-growth/</u> accessed July 2024.
 - 8. Medicines and Healthcare Products Regulatory Agency (MedRegs). *The past, the present and the future of clinical trials transparency in the UK.* 2021. Available from: https://medregs.blog.gov.uk/2021/12/22/the-past-the-present-and-the-future-ofclinical-trials-transparency-in-the-uk/ accessed July 2024.
 - UK Government. Department of Health and Social Care. The future of clinical research delivery: 2022 to 2025 implementation plan. Available from: <u>https://www.gov.uk/government/publications/the-future-of-uk-clinical-researchdelivery-2022-to-2025-implementation-plan accessed July 2024</u>
 - 10. Mullard, A. Shifts in the clinical trial landscape. *Nat Rev Drug Discov*, 2024; **23**: p.239.
 - 10. IQVIA Institute. *Global trends in R&D 2024: activity, productivity and enablers. Annual trend report from the IQVIA Institute for Human Data Science.* Available from: <u>https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers.</u> Accessed: July 2024.
 - 11. Bhatt A. *New clinical trial rules: academic trials and tribulations.* Perspect Clin Res 2019; **10**(3): p. 103–105.
 - 12. Blüme A, et al. Investigator initiatied trials versus industry sponsored trials translaltion of randomised controlled trials into clinical practice (IMPACT). BMC Med Res Methodol 2021; **21**: p. 182
 - 13. World Health Organisation (WHO). *Number of clinical trial registration by location, disease, phase of development, age and sex of trial participants (1999–2021)*. 2021. Available from: <u>https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development</u> accessed July 2024.
 - 14. Fundytus, A., et al. *Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.* Clin Oncol, 2022; **34**(1): p. 28–35.
 - 15. Capone, G., et al. Accelerating clinical trails in the EU (ACT EU): transforming the EU clinical trials landscape. Nat Rev Drug Discov, 2024 doi: 10.1038/d41573-024-00085-5 [published Online First: 20240523].
 - 16. Jefferson, L., et al. *No difference found in time to publication by statistical significance of trial results: a methodological review.* JRSM Open, 2016; **7**(10): p. 2054270416649283
 - 17. Mongin, D., *Time to publication and time-lage publication bias for randomized trials on connective tissue disease.* ACR Open Rheumatology, 2023; **5**(8): p. 420–25.
 - 18. Atassi, N., et al., *Analysis of start-up, retention, and adherence in ALS clinical trials.* Neurology, 2013. **81**(15): p. 1350–5.
 - 19. Kantarjian, H., D.J. Stewart, and L. Zwelling, *Cancer research in the United States: Dying by a thousand paper cuts.* Cancer, 2013. **119**(21): p. 3742–3745.
- 20. IMD World Digital Competitiveness Centre. *World digital competitiveness ranking* 2022. 2022. Available from: <u>https://www.imd.org/centers/world-competitiveness-</u> <u>center/rankings/world-digital-competitiveness/</u> accessed July 2024.

21.

22.

European policy priorities. 2022. Available from:

accessed July 2024.

accessed July 2024.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Ρ	ĉ
1	
2	
3	
<u>م</u>	
5	
د م	
0	
/	
8	
9	
1	(
1	1
1	;
1	-
1	-
1	-
1	-
1	е
1	7
1	8
1	c
כ	۔ ر
2	1
2	
2	4
2	2
2 2 2	2
2 2 2 2	
2 2 2 2 2	
2 2 2 2 2 2 2	
222222	
22222222	
22222222	
22222223	
222222233	
2222222333	
22222223333	
2222222333333	
222222223333333	
22222222333333333	
∠2222222333333333333333333333333333333	
22222222333333333333333	
22222223333333333333333333	
222222233333333333333333	
22222223333333333334	
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
22222233333333333444	
22222233333333334444	
222222233333333333444444	
22222223333333333444444	
2222222333333333444444444	

26

A.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



	Population	GDP per	Annual GDP	GDP spent	Mean
	(Million)	capita	projected	on	expenditure
		(US\$ per	growth rate (%)	healthcare	per capita
		capita)		(%)	(US \$)
USA	313.1	54,640	2.8	7.9	4,317
UK	62.6	32,225	2.3	7.3	2,352
France	63.8	38,870	1.7	8.6	3,343
Germany	82.1	44,985	2.3	8.4	3,779
Italy	60.7	35,067	1.5	6.8	2,385
Spain	46.6	33,720	2.8	8.9*	3,001*

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. *Data was not available for Spain when the search was conducted, and subsequently checked in 2022.



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Fig 3

а

1	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
14	
15	
16	
17	
18	
19	
20	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
22	
24	
34	
35	
36	
37	
38	
39	
10	
40	
41	
42	
43	
44	
45	
46	
40	
4/	
48	
49	
50	
51	
52	
52	
C	
54	
55	
56	

	Country	Median start up duration (Days)	Median enrolment rate (Patients site / month)	Proportion of non-enrolling sites (%)
	USA	111	0.5	15.9
	UK	186	0.4	27.9
Haematological	France	141	0.6	18.7
cancers	Germany	92	0.6	25.9
	Italy	122	0.5	6.5
	Spain	195	0.6	16.2



Maximum expected CTA approval Maximum expected site ethics approval

BMJ Open

Has the UK lost its position as a destination for world leading clinical research? A comparative analysis of haematological cancer clinical trials performance before Brexit

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-086058.R2
Article Type:	Original research
Date Submitted by the Author:	15-Oct-2024
Complete List of Authors:	Arora, Meena; Onconova Therapeutics Inc, Kilcoyne, Adrian; Celularity Inc Bolodeoku, Dr; JB Consulting (MDP) Ltd, 1 Bell Street el Baghdady, Assem; King's College London
Primary Subject Heading :	Public health
Secondary Subject Heading:	Oncology, Health policy
Keywords:	Leukaemia < HAEMATOLOGY, Health Equity, Clinical Decision-Making





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Has the UK lost its position as a destination for world leading clinical research? A comparative analysis of haematological cancer clinical trials performance before Brexit

Arora M (0009-0007-7608-457X), Kilcoyne A (0009-0002-7882-8927), Bolodeoku J (0000-0003-4261-9285), el Baghdady A (0009-0004-4673-5034)

AFFILIATIONS:

 Meena Arora, Vice President, Global Medical Affairs and R&D, Onconova, USA; Visiting

Lecturer, King's College London, UK

Adrian Kilcoyne, Chief Medical Officer & Executive Vice President, Cellularity Inc., New

Jersey, USA

John Bolodeoku Visiting Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Assem el Baghdady Senior Lecturer, Centre for Pharmaceutical Medicine Research,

Institute of Pharmaceutical Science, King's College London, UK

Corresponding author

Meena Arora, meenakarora@icloud.com

Summary

What is already known on this subject

- Clinical trials are of critical importance to the UK.
- UK research is among the highest quality globally and has been evaluated in this study with a focus on haematological cancer trials against the USA and reference European countries France, Germany, Italy and Spain.
- Despite the UK providing quality research of clinical and economic importance, the proportion of global clinical trials conducted within the UK is declining.

What this study adds

• Reduced share of global research, particularly Phase 2 clinical studies, risks a potential loss of research leadership in the UK, which could have extensive

 implications for patient's ability to access innovative therapies as well as material economic consequences for the UK.

- Whilst volume of clinical research may be declining in the UK, the quality of research being conducted in the UK remains high as does commitment to completion of studies being undertaken.
- This study demonstrated that outputs from UK clinical trials in the form of publication are of the highest value of all countries evaluated appearing in high impact journals with the highest citability indices.

or occition in the second

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

ABSTRACT Objectives

 To understand the competitive position of the UK in comparison to Europe and USA for haematological cancer clinical research.

Design

Using commercially available databases, clinical trial numbers, their effectiveness and publication outputs were evaluated in two analyses: a macro development and a research activity and performance analysis.

Data sources

The following databases were used for this analysis: Organization for Economic Cooperation and Development (OECD), Thomson Reuters Incidence and Prevalence, the Cortellis Clinical Trial Intelligence, the Clarivate Cortellis Innography Patent Intelligence, Thomson-Reuters Cortellis Regulatory Intelligence, Thomson Reuters Web of Science and data from the Centre for Medicine Research (CMR).

Eligibility criteria

European countries with comparable geographic, healthcare standards and economies and the USA as the largest country where research is undertaken. All haematological oncology clinical trials from Phase 1 to Phase 3 were included.

Data extraction and synthesis

All data were retrieved in September 2017 and macroeconomic data were reviewed in 2022; haematological cancer data were restricted to leukaemias generally as a surrogate reference for haematological oncology indications; research output publication data were evaluated using specific MeSH/keyword search terms between 2010–2017. Key metrics explored included healthcare expenditure per capita, study experience across countries, comparative capability of each country for clinical trial implementation, clinical trials' performance and impact of research as measured by impact factor and citation metrics of publications.

Results

Revenue for clinical studies is lower in the UK than European comparators. All studied countries had comparable leukaemia prevalence rates, but the UK spent least per capita on healthcare versus France, Germany, Spain and USA. The number of clinical studies in the UK showed a decline compared with other European countries. Clinical trial implementation

was lowest in the UK (n=380) versus Germany (n=665), France (n=643), Spain (n=632), Italy (n=538), and the USA (n=3,254). Registered versus active clinical studies suggested the USA had the highest number underway (n=824), with UK ranked fourth of five European countries (Germany=239, Italy=232, France=211, UK=177 and Spain=141). However, the UK had the highest completion rate of Phase 3 studies it did initiate (n=154, 87%) and performance was comparable with Germany (n=188, 78.7%) and France (n=151, 71.6%). When analysed by Phase, the UK was the second highest European performing country (n=121) for Phase 2 study completion compared with Germany (n=182) both less than the USA (n=345). The UK completed the most Phase 1 studies compared with other European countries, only second to the USA (n=31 versus n=126). However, the UK clinical trial performance metrics were negatively impacted for the UK compared in comparison other European countries with respect to clinical trial application process, timelines, ethics committee approvals, median time to start up and rate of non-enrolling sites. The UK was slower to initiate studies (median 186 days) versus Germany (92 days), France (141 days), Italy (122 days) and only marginally faster than Spain (195 days). Whilst median enrolment rates were comparable across all countries, the UK had the highest proportion of sites that failed to enrol any patients (despite regulatory timings being comparable to Germany [90 days] and France [95 days]). Publication of data following clinical trials in the UK however is robust and of the highest quality compared with other countries, judged by journal placement and publication citations. The UK publishes high quality, diverse research with citation rates (11.8) from clinical studies which is higher than every other country, including the USA who publish five-fold more publications per year.

Conclusion

Whilst research in the UK remains amongst the highest quality and value globally, the UK may be losing its position globally as an attractive destination for executing clinical trials. This may be trend that is recognised by the UK Government, but it is vital to reverse the trend of clinical trial decline and to improve the UK's economic outlook for the UK, and patient early access to innovative cancer medicines.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Strengths and limitations of this study

- The strengths of this study are the use of robust commercial databases that give an accurate overview of clinical trial volumes in the UK and reference countries, breakdown of clinical trials by phase and data relating to enrolment.
- Limitations include the timing of data analyses which cannot explore data in the years up to and following the signing of the Brexit exit agreement at the end of 2021 and is explored in ongoing research.
- Another limitation is the assumption that publication in the UK reflects the prestige of UK researchers and work undertaken in the UK; the impact of publication in the UK because of other factors was not evaluated.

INTRODUCTION

Clinical trials are critical to provide early access to life saving medicines for patients, improve future standards of clinical care and inform future clinical practice that optimises patient outcomes.

Development of new therapies is expensive with costs estimated from \$765.9 million to \$2771.6 million depending on the indication. [1] Clinical trials by the pharmaceutical and biotech industries are an essential part of the clinical trial mix of industry and academic sponsored studies which support clinical development of new therapeutic options to advance patient outcomes. Cost and complexity of development of novel molecules and clinical trial infrastructure means that industry and academic collaboration in clinical trials is critical.

Industry sponsored clinical trials provide material economic benefits to healthcare in the UK through revenue generation. Clinical trials, regardless of their funding, also provide opportunities for patients to access novel medicines and resources for the duration of the trial and maybe beyond into long-term extension phases. In Italy, 92% of funding for clinical studies was derived from pharmaceutical industry, quantified at more than €750 million. [2] It was further suggested that industry sponsored clinical trials also further benefit country healthcare system in terms of avoided costs, whereby patients enrolled into clinical trials reduce financial burden on healthcare systems for the duration of the clinical trial. [3] Two recent studies have suggested that for every Euro invested by the pharmaceutical industry there is a net financial gain for the overall economy of at least 25%. [4,5] A study in Austria suggested additional positive outcomes of clinical trials including employment of specialised staff including researchers, medical and managerial personnel so that clinical trials provide an 'employment multiplier' of 1.66, [4] a benefit that may also be realised in other geographies where clinical trials are carried out.

Clinical trials enable clinicians to provide treatment within the trial setting without charge, and often subsidise care through free diagnostics and other treatments and provide funding for administrative and operational work. Additionally, it ensures that physicians remain at the cutting edge of scientific advances as they get first-hand experience in applying the newest scientific advances.

Clinical trials provide benefits to both clinicians and patients. For patients, trials provide access to innovative and potentially life prolonging medications years in advance of regulatory approval and reimbursement. And for clinicians, clinical trials enable participation

in cutting edge medical research that can improve and shape current and future standards of care. However, for patients it must be noted that access to innovative, experimental treatments is not risk free, and participation in such trials runs a risk of experiencing adverse events, possible toxicity or lack of drug effectiveness.

In areas such as oncology access to innovative medicines remains an area of high unmet need. This unmet need is recognised by the UK Government. A recent UK Commons Cancer Services report April 2022 stated: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in National Health Service (NHS) cancer care." [6] The outcome for UK patients relies on a complex interchange between available infrastructure, access to therapies and standard of care. It is difficult to fully understand from this report, and was not evaluated, if poorer patient outcomes in the UK was due to lower opportunities to participate in clinical trials, but it is an important part of the treatment journey that warrants further investigation. Clinical trials do provide an avenue for patients to access novel medications so it follows any impact on clinical trial start up, implementation, and delivery may impact patient access and maybe outcome. However, it is likely to be minor compared with issues of NHS waiting lists that can impact cancer pathways for patients.

The attractiveness for a country to implement and deliver clinical trials relies on a combination of factors including market size, regulatory timelines, costs of implementation and clinical trial outputs. Data from the Association of British Pharmaceutical Industry (ABPI) suggest that despite applications for clinical trials to the UK Medicines and Healthcare Regulatory Agency (MHRA) remaining stable, the number of industry sponsored studies has declined over the course of 2017–2020, reducing from 667 to 508, a decrease of 24%. [7]

Now that the UK has left the European Union, exploring the potential for the UK as a major player in clinical trials is essential. Brexit poses additional challenges to the UK in attracting clinical trial implementation including barriers to data sharing, the removal of regulatory mutual recognition, compatibility of regulatory and medicine research approaches, information access and health security. [8]

In this analysis to explore the attractiveness of a country for implementation of clinical trials programmes the following points were considered:

country population

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- expenditure on healthcare per capita
- prevalence of disease
- clinical trials experience
- clinical trial and ethics approval processes and timelines

However, understanding exclusively the number of clinical trials within a country is to ignore the scope and value of research being done. To address this an analysis of clinical trial performance and calibre of research by publication and patent applications was undertaken, to give an overall view of not only research volume but also its value. This is an imperative because whilst clinical trial volume may be of significant financial benefit to a healthcare economy, it is the scientific value that is important to progress new therapies for patients and improve outcomes.

The aim of this research was to explore and understand the attractiveness of the UK as a destination for running clinical trials compared to reference European countries and to understand requirements for change to ensure the UK can become and remain an essential and attractive country for clinical trial development and implementation. This research also compared European and UK data against that for the USA as a high-income country with comparable healthcare standards. This research provides a snapshot of the UK's standing versus key European countries and the USA, using haematological cancer as an example, with respect to clinical trial development, implementation, and regulatory approval.

METHODS

Countries across Europe were included in this study (France, Germany, Italy and Spain) as comparators for the UK. These countries were evaluated as all were considered high-income countries with comparable healthcare standards and economies, geography and socioeconomic factors. The USA was also included as a comparator high-income country with a robust approach to research, comparable to, but different from Europe.

Data to explore country wealth and healthcare expenditure, disease prevalence, clinical trial implementation and publication of clinical trial data were collated. Country economic data were established using data from the Organisation for Economic Co-operation and Development (OECD Paris, France), and whilst healthcare spend cannot always provide insight into the quality of healthcare delivery, countries were chosen for their approximate comparability. Data for disease epidemiology was provided from the Thomson Reuters' Incidence and Prevalence database (IPD, Clarivate Inc. Philadelphia, USA). The IPD covers over 4,500 diseases, procedures, symptoms and other health issues for incidence,

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

prevalence, morbidity, mortality, comorbidity, treatment or diagnosis rates and cost. The IPD tracks and reports the epidemiological content from more than 280 medical journals and over 35 government and industry agencies. It is updated every 4 weeks and so is an efficient single source to access current data. Limitations of the databases used meant it was not possible to evaluate specific haematological cancers (Leukaemia, Multiple Myeloma, Relapsed Refractory Myeloma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma, Follicular Lymphoma, CNS Lymphoma) and so leukaemia was adopted as a surrogate for all haematological cancer subtypes across the countries studied. Clinical trial numbers and stage of development were evaluated using data extracted from Cortellis Clinical Trial Intelligence (extraction date September 2017) (Clarivate Inc. Philadelphia, USA). To analyse the number of completed haematological cancer studies within development Phases 1, 2 and 3 for each of the 6 countries, Clarivate Cortellis Clinical Trial Intelligence was searched. A modified Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) analysis approach was used to identify all studies that had been conducted within the haematological cancer disease area in each of the countries. The Cortellis Clinical Trial Intelligence database is a single source of fully searchable and indexed global clinical trial content for more than 400,000 clinical trials evaluating drugs, drug-like entities, treatment/prophylactic medical devices, biomarkers, biologics, and vaccines. Data is populated daily from thousands of global sources, including more than 25 international clinical trial registries (including Clinical Trials.gov, EudraCT, ISRCTN, JapicCTI etc), press releases, literature articles and conference reports.

To evaluate the value of clinical studies as well as volume, measures such as trial completion, published data and patent applications leading to possible useable drug entities were explored using Thomson Reuters Cortellis Regulatory Intelligence and Thomson Reuters Web of Science (both Clarivate Inc. Philadelphia, USA). The Thomson Reuters Cortellis Regulatory Intelligence, is a single, comprehensive source for global regulatory information and contains more than 143,000 current and historical documents from over 200 regulatory sources covering more than 70 countries. Data relating to the clinical trial application (CTA) and the site ethics submission process and estimated duration was extracted from Cortellis Regulatory Intelligence for each of the 6 countries.

MeSH and keyword search terms for both American and British English were used. Parameters for publication searches were: "Leukemia" OR "Leukaemia" OR "Myeloma" OR "Myelodysplastic syndrome" OR "Myelodysplasia" OR "Myelofibrosis" OR "Myeloproliferative

neoplasm" OR "Hematological malignan*" OR "Haematological malignan*" OR "Hematological cancer" OR "Haematological cancer" OR "Blood cancer" OR "Bone marrow cancer" OR "Plasma neoplasm" OR "Plasma cell neoplasm" OR "Plasmacytoma" OR "Liquid tumor" OR "Liquid tumour" OR "Hodgkin* " OR "Waldenstrom macroglobulinemia" OR "Reed-Sternberg cells" OR "Lymphoma" OR "B cell neoplasm" OR "T cell neoplasm" OR "Natural Killer cell neoplasm" OR "NK cell neoplasm" OR "Heavy chain disease" OR "Lymphomatoid granulomatosis".

Performance of clinical trials as a method to establish the attractiveness of a country for clinical trials was evaluated using data from the Centre for Medicine Research (CMR) (Clarivate Inc. Philadelphia, USA) and the metrics of trial start up, trial site recruitment rate and clinical trial site efficiency. The CMR database contains biopharmaceutical company sourced and validated performance metrics for over 400,000 sites and over 25,000 sponsorled, investigational drugs trials and is considered a gold standard for clinical performance metrics across the pharmaceutical industry. Trial start-up was measured as median time from the end of the clinical trial application (CTA) approval process to enrolling the first patient. Recruitment rates were assessed by the number of patients enrolled per site per month. Evaluation of site efficiency was measured by the proportion of sites which were initiated to start trials but did not enrol any patients. Patents for clinical medicines in haematological cancers were analysed using Thomson Reuters Web of Science (WoS) and Thomson Reuters Cortellis (including Derwent World Patents Index) databases. These databases were selected as they contain multidisciplinary content covering 12,000 of the highest impact journals and 150,000 conference proceeding papers, as well as data on product pipelines sourced from press releases, company reports, industry deal reports and conference abstracts.

No ethics approval was required for this analysis.

Patient and public involvement

No patient or public involvement was required in this analysis.

RESULTS

Analysis of countries studied

Country wealth and healthcare expenditure

Results from the macro development analysis indicated that population size and healthcare spend were not proportional. The highest population from OECD data was observed in the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

USA (313.1 million) with a GDP percentage spend of 7.9%. These data compare with Germany whose population at 82.1 million is a third of the USA but spends 8.4% of its GDP on healthcare. For both countries GDP growth rates were comparable (Figure 1). GDP spend on healthcare as a proportion of mean expenditure per capita was lowest in the UK at less than 5% (Figure 1). Data for Spain was not available from the OECD but indicated a GDP spend of 8.9% – the highest of all countries evaluated with a population of 46.6 million.

Investment in healthcare suggested highest expenditure in the US with the UK and Italy the lowest investing countries per capita. (Figure 1). USA healthcare expenditure per capita was almost double that of the UK (\$4317 versus \$2532). Comparison of GDP per country and the contribution to global GDP was noted as: France GDP \$3,533 billion, Germany GDP \$5,011, Italy GDP £3,180 billion and the UK whose GDP was \$3,479 billion all of whom contributed 2% to global GDP, and Spain GDP \$2,301 billion of which 1.3% was contributed to global wealth. Healthcare spending in Germany, France and Spain was comparable (range 8.6%–8.9% GDP). When mean expenditure on healthcare per capita was examined the UK ranked the lowest of all countries evaluated (Figure 1).

Disease prevalence across comparator countries

Prevalence of leukaemia across all countries in the study was broadly comparable (Table 1), ranging from 32.3/100,000 population in the UK to 45.6/100,000 population in France. As expected, the USA, with a population size more than three times larger than the largest European country Germany, the estimated total number of patients with leukaemia was greater than 100,000. The UK had a projected leukaemia population equivalent to Italy and more than 9,000 patients fewer than both Germany and France.

Table 1: Prevalence of Leukaemia*	data by	country	and	estimated	number	of total
patients						

Therapeutic area	Country	Prevalence (per 100,000 pop)	Estimated total patients
Haematological cancers*	USA	33.1	103,636
	UK	32.3	20,220
	France	45.6	29,093
	Germany	34.4	28,242
	Italy	34.3	20,820
	Spain	37.9	17,661

*To address data meaningfully, prevalence data was limited to leukaemia only. Leukaemia included acute lymphocytic leukaemia; chronic lymphocytic leukaemia; acute myeloid leukaemia; chronic myeloid leukaemia.
Evaluation of clinical studies across comparator countries Implementation of clinical trials from Phase 1 to Phase 3 registration trials

The number of active haematological cancer trials underway was evaluated against the number of registered studies. In 2017 the number of active haematological cancer clinical studies was lowest in both the UK and Spain (n=177 and 141, respectively) compared with all other countries (Figure 2a). The UK lagged considerably behind Germany, Italy and France, despite having a comparable population size and mean healthcare expenditure spend to Italy.

Most haematological cancer trials were conducted in the USA (n=3,254) with the UK and Italy having the lowest number of trials (n=380 and 538, respectively) (Figure 2b). The distribution of these studies by country and phase is shown in Figure 2 and demonstrated a predominance of Phase 1 and Phase 2 haematological cancer studies in the USA (Figure 2c). The UK conducted a comparable number of Phase 1 haematological cancer studies with other European countries (Figure 2b). Phase 2 clinical trials were the most commonly implemented trial phase in the UK but the numbers of Phase 2 studies was lower than Germany, France and Italy who conducted the most Phase 2 haematological cancer studies outside of the US (Figure 2b).

The number of Phase 3 haematological cancer studies was broadly comparable across Europe (n=239–257) except for Spain who conducted only 171 Phase 3 studies. The UK conducted 240 Phase 3 studies and ranked third among European countries suggesting that the UK performs well with respect to this phase of study. (Figure 2b) As expected, European figures were considerably lower than the number of Phase 3 studies conducted in the USA (n=402) (Figure 2b).

Clinical trial volumes were evaluated through exploration of the number of clinical trials completed by phase and country (Figure 2c). These data suggest that whilst clinical trial volume in the UK may be low in comparison to other European countries, once initiated clinical trials in the UK are very likely to be completed. For Phase 2 and 3 studies, the UK was third of all comparator countries completing more studies behind only the USA and Germany, and for Phase 1 studies the UK was the highest European country completing studies with only the USA completing more.

Not surprisingly, the number of clinical trials completed in the USA was comparable to the sum of all European countries considered in this study. The USA had the highest rate for trial completion across all phases and Spain and Italy the lowest. With respect to trial completion

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

across Phases 1–2 the USA trial completion counts were at least 2-fold greater than any individual European country included in the analysis (USA n=728; Germany n=396; UK n=306; France n=245; Spain n=225; Italy n=226). Study completion by Phase for USA was 4-fold higher for Phase 1. For Phase 3 clinical studies USA rates of trial completion were higher but less pronounced than overall data (30–50% higher than European countries) and the USA completed approximately 27% more studies than Germany, the highest-ranking European country. In Phases 2 and 3 the UK was the second highest completing country in Europe outside of Germany.

Analysis of clinical trial effectiveness

Clinical trial implementation

Clinical trial implementation and completion provide an insight into research across comparator countries but do not provide insight into the potential impact and effectiveness of clinical trials and their outcomes in those countries. A review of clinical trial application and ethics' approval times were demonstrably shortest in the USA (Figure 3a) for national review and approval. Spain and Italy had the longest processes at 60 days for CTA approval and 60 days for ethics approval. For the UK ethics' approval times were a 30-day maximum and CTA approval maximum of 60 days and this was the same as that for Germany (Figure 3a,b).

Evaluation of clinical trial effectiveness across countries is shown in 3a,b demonstrating that Germany was the fastest European country in clinical trial start up being two-fold faster than the slowest European country, Spain. The UK was only marginally faster than Spain with a median of 186 days from approval to trial start up. The UK also had the highest rate of nonenrolling clinical trial sites at 27.9%, an attrition rate that was comparable with Germany (Figure 3b), but almost twice that of the USA and four times higher than Italy. Across all countries median enrolment rate per site over time was broadly comparable.

Analysis of clinical trial outcomes

Research impact analysis

To explore the impact of clinical trial research across the studied countries the volume and impact of clinical trial derived data was evaluated. Turning research implementation into outputs as measured through publications, citations and patents was highest in the USA, followed by Germany, with Spain lagging (Table 2). Whilst total publication numbers were similar between Italy and UK (11,143 and 10,579, respectively) citations derived from UK published research was the highest of all countries evaluated (Table 2).

With respect to calibre of research publication diversity the UK was a smaller entity for clinical trials, but research was published in high calibre, highly cited journals ranking third of all countries evaluated, including the USA. Similarly, the number of patent applications arising from UK-sited clinical trials was high, ranked third of all countries evaluated and the second highest European country (Table 2). Evaluation of research diversity of research in the UK with respect to haematological cancers derived from keyword representation suggested the UK has a broad diversity of research and was the only country where there was a predominance of publications in childhood leukaemia, a trend not reflected elsewhere.

Table 2. Research output by country 2012–2017 as evaluated from publications and patents.

	Total number of publications	Total number of authors	Total number of citations	Number of citations per publication (n)	Proportion of publications in high Impact Factor journals (%)	Number of patent applications related to clinical trials
USA	51,574	92,064	533,973	10.4	8.3	6,888
UK	10,579	14,920	125,172	11.8	7.5	729
France	9,132	15,091	101,283	11.1	7.4	525
Germany	13,580	19,163	129,984	9.8	5.9	1,037
Italy	11,143	18,741	97,554	8.8	5.0	311
Spain	5,361	10,162	57,388	10.7	6.5	166

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

DISCUSSION

Clinical research has the potential to advance science and revolutionise outcomes for patients. There are economic, healthcare and societal benefits for the UK being part of this milieu. However, clinical trials require investment in terms of time, finance and researcher training, which is outweighed by the potential benefits both to patients and society.

Clinical trial implementation

In this analysis the maximum expected time to achieve a CTA for each country was calculated. From this it was clear that the UK and Germany have the fastest approval times for CTAs and ethics approvals. Slower time in other countries such as Spain (120 days vs 90 days for UK) reflects the sequential nature of processes for a favourable opinion from the Clinical Research Ethics Committee (CREC/EC), the agreement from the management of the centre where the study is to be conducted and the authorization of ethics committees and the Spanish Agency of Medicines and Medical Devices (AEMPS). By contrast approval times in the USA were the shortest, but our data does not reflect any inter-state differences that may arise.

However, with respect to clinical trial start up in 2017 the UK was slow compared with Germany. The difficulties in starting clinical trials in the UK has been noted and Governmental interventions have been implemented to reverse this trend in the post-COVID era including an increase in funding and removal of capital investment taxes for medicinal development in 2023 and the policy paper of the future of clinical research implementation plan 2022–2025 published in 2022.[9] There are glimmers of hope that these initiatives are showing promise. However, with a new Government in place in the UK, it will be imperative that the strides made to keep the UK competitive within clinical trial implementation and delivery is maintained and enhanced.

Clinical trial performance

Our research suggests that whilst the UK in 2017 was performing relatively well compared with the rest of Europe, with some greater expertise in Phase 1 and Phase 2 studies, it is losing ground. Overall, the UK conducted fewest haematological clinical trials, ranking fourth out of five European countries for Phase 2 studies although better rankings were observed for both Phase 3 and Phase 1 studies. Whilst it must be noted that differences between countries were not substantial when ongoing studies were evaluated, the UK overall was ranked fourth out of five, with only Spain conducting fewer studies in the year of investigation. This is despite the UK having similar disease prevalence and healthcare

expenditure to higher performing countries like Germany. Healthcare spend per capita may not be translatable to delivery of high-quality healthcare, but when GDP percentage values for healthcare are also juxtaposed with ongoing haematological cancer trials as of 2017, the UK lagged behind almost all European countries, bar Spain, despite comparable prevalence data across all countries studied. We have conducted a second study exploring clinical study implementation over time, currently unpublished, which suggests that clinical trial numbers in the UK declined after 2017 to near 2011 levels, which is an effect not seen in comparator countries. Whilst this companion study represents the pre-COVID-19 environment a recent report has indicated that clinical trials initiated by industry has reduced by 15% to 4,900 trials in 2023 compared with 2022 and more than 32% lower than the peak in 2021, which was driven by COVID-19 trials. [10,11] The authors of this report suggested a potential driver of this decline was historic delay in trials startup or completion and that clinical trial starts in oncology, metabolic/endocrinology, immunology and neurology together were reduced by approximately 8%. [10,11] Our data gives a snapshot of haematological oncology trials which is consistent with other published reports in other areas of clinical research such as the IQVIA report published in 2024. [11]

One element that cannot be evaluated from the database results is the sponsor of clinical trials evaluated whether academic or industry sponsored. Recent data suggests that sponsorship of clinical trials by academic sources is robust with up to 62% of clinical trials sponsored in this way. [12] Academic sponsored studies encompass a wide range of study types from investigation of novel medicines or techniques to evaluation of real-world clinical practice, whilst industry sponsored study most often focuses on the investigation of novel medicines in new therapeutic areas. However, publication of results from academic clinical trials lags behind that of industry sponsored studies, likely due to reasons of restricted financial or personal capacity or academic priorities.[13] Either way, limiting publication of data risks an overall publication bias in available data, rectification of which would benefit patients and researchers alike and demonstrate a continued need for a diverse clinical trial landscape.

In oncology specifically, a review of trials by the World Health Organisation from 2012–2017 indicated that 71% of trials were industry funded. [14] In the UK, the ABPI report indicated a decline from 2012 in clinical trials in the UK [7], a position supported by Cancer Research UK. As we have seen, Governmental interventions have been devised and implemented to reverse this trend but fledgling programmes such as this will need time, investment and Governmental commitment to ensure they thrive.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Patient population sizes were between 17,661 in Spain and 29,093 in Germany, but when pooled across Europe were broadly comparable with that in the USA (116,036 versus 103,636). The USA conducted almost six times as many haematological cancer clinical trials compared to the UK, a trend that was replicated across clinical studies overall. In this study the number of clinical trials in the USA was not adjusted for population and so clinical trial volume was predominantly a function of population size, and explains why the USA, with a fivefold larger population, ranks first. With such access to patients and a comparable prevalence of leukaemia to the UK and other European countries their ability to engage with eligible patients outranks individual countries in Europe. Evaluation of trial completions shows that the USA consistently ranked highest in terms of completion and therefore experience. These data are unsurprising given its much larger population compared to each individual European country included in the study and reflects trends in clinical trials overall. [15]

The highest trial completion in Europe was seen in Germany, perhaps reflecting their high levels of experience of running clinical trials as defined by this analysis. For the UK and France, the picture was a little more variable. The UK had a high rate of study completion for Phase 1 clinical studies specifically, perhaps reflective of the UK's experience in this area. Importantly, if the proportion of completed haematological cancer trials against the number of active trials was evaluated it was apparent that whilst numerically the UK may have implemented fewer clinical trials it does drive them through to completion; third behind the USA and Germany for Phase 2 and Phase 3 studies and second only to the USA for Phase 1 studies. These data suggest that clinical trial research in the UK may be hindered numerically, but clinical trials started in the UK are typically completed and published with high impact and highly cited published data.

Clinical trial effectiveness

An overview of clinical trial efficiency using proportional data provided a different perspective. As shown in Figure 3, Italy, a less populated country, was most efficient in clinical trial start up, recruitment and enrolment, with the USA second and the UK fifth ahead of Spain. Data suggest that the UK has lost some impetus in initiating and driving clinical trials with long start-up times to initiate studies which will have consequences for the UK economic and for patient access to innovative medication. This trend, it is hoped, will be halted and reversed.

Approval time is a key factor in determining the attractiveness of a country for clinical trial roll out. Typically, in any country a CTA needs to be reviewed by a number of organisations in addition to central and local ethics committee reviews. Depending on the specific country, review processes may be sequential or in parallel, with each review having an expected maximum duration. From the various country specific processes, it was possible to calculate a maximum expected review time for a CTA. In the UK, authorisation from the MHRA is mandatory to conduct a clinical trial alongside favourable opinions from relevant Ethics Committees. Applications to the Ethics Committee and the MHRA may proceed in parallel or sequentially, depending on the wishes of the sponsor organisation. By comparison, in Spain, it is necessary to obtain a favourable opinion of the corresponding Clinical Research Ethics Committee (CREC/EC), the agreement from the management of the centre where the study is to be conducted and the authorisation of ethics committees and the Spanish Agency of Medicines and Medical Devices (AEMPS) processes which may or may not proceed in parallel, but are often enacted sequentially. By contrast, it is interesting to note that with respect to clinical trial implementation the UK was ranked low, typically fifth of the six countries evaluated. At 186 days, UK authorisation took twice as long as Germany and was a third longer than the USA.

The UK is uniquely placed for clinical trial implementation by merit of the National Health Service (NHS) whose infrastructure can provide a well characterised patient population for studies, combined with world class medical capability. However, as a largely Trust-based decentralised system any advantages may be diminished, and this may explain the UK rankings among other European countries. Clinical trial providers often need to undergo lengthy negotiation with the NHS before a trial can be set up, resulting in slower start up times to enrolment, higher trial costs per patient than other European countries and a mitigation of any advantages a shortened maximum time to ethical approval might give a trial sponsor. However, it is hoped that initiatives underway to improve clinical trial implementation in the UK may soon reap benefits for the UK economy and patients.

This analysis could not evaluate how many trials undertaken in the studied countries led to licensed, regulatory approved and available medications accessible to patients. However, the number of patents related to clinical trials can be surmised to be a surrogate marker for molecules that are considered promising. In Germany the number of patent applications in 2017 was more than 1,000 with 30% fewer applications lodged in the UK in the same period (n=729). This places the UK only second in Europe behind Germany which suggests that the patent environment in the UK is quite attractive. However, given that the UK is 30% behind

Germany it is tempting to speculate that Germany has more innovation driving patent applications and their high standing for clinical trial volume and completion or have compensatory mechanisms in place which make it an attractive location to lodge a patent. However, with the UK and Germany having comparable times to ethics and CTA approval and the UK having only 30% fewer patent applications Germany's innovation alone is insufficient to explain the disparity between Germany and the UK. Going forward, it would be interesting to explore in a future study, how Governmental intervention, the settling of the economic landscape post-Brexit and the renewed investment in clinical trials that have resulted following COVID-19 change the landscape for clinical trials and patent applications in the UK. The changing Governmental landscape in the UK may benefit these improvements further with increased investment or political willing and it will be interesting to evaluate the combined impact of these factors in the future. Within Europe the Accelerating Clinical Trials (ACT) programme [16] is similarly purported to transform the EU clinical trials landscape and so the impact of this on the UK, as a non-EU member is as yet unknown, and this warrants further investigation.

Contrasting volume against quality as a metric for attractiveness

Volume analysis alone, however, provides only a limited perspective. Understanding the value and reach of clinical trial outcomes is of equal importance and is vital to progress therapies for future approval and use in patients. Analysis of research output and quality was used as a surrogate marker of clinical trial performance. In the UK, it was noted that clinical trials when completed were typically published in high ranking, highly citable journals. Such wide publication of UK-led data in reputable journals demonstrates that clinical data derived in the UK is widely accepted by the academic and clinical community as being of high quality. The UK's demonstratable drive to publish data ranked it second in Europe in terms of publication volume behind Germany and third when the USA is included. However, the UK ranks first in Europe with respect to number of citations per publication and only second behind Germany for total citations. Consideration of publication citations which were highest in the UK infer that research in the UK is robust, relevant and interesting and we would translate this inference as a surrogate marker that the UK is a deliverer of high-quality research. Empirically, it might be assumed that there will be substantial lag between the end of a clinical trials, regardless of its phase and publication in a highly reputable journal. Whilst this may be true in some instances and is believed anecdotally, data evaluating the time lag between the end of Phase 2 and Phase 3 studies suggests this is not the case with a study evaluating clinical trial study publications in the BMJ, JAMA, Lancet and the NEJM indicating a median time from trial completion to publication of only 431 days (Range 278-618) which was not statistically different for positive or negative results.[17,18] Time-lags in data

BMJ Open

dissemination however, when they do arise can be acknowledged to impede knowledge diffusion, and in the case of novel medicines may impact time to regulatory approval and reimbursement which may require published data for their evaluation. However, it is anticipated that the publication data presented here from 2017 whilst it might reflect clinical data completed in the previous year or two, remains a robust marker of high-quality data dissemination, and we would anticipate that this has continued over time regardless of any changes to the clinical trial landscape in the UK.

Positioning the UK as an attractive clinical trial partner

The UK has demonstrated instances where academic clinical trial infrastructure can align to deliver effective, timely and impactful results. Examples of this include the RECOVERY trial evaluating approved drugs in the management of COVID-19 and the STAMPEDE trial exploring the role of radiotherapy in prostate cancer.[19,20] Whilst COVID-19 was a once in a generation event, promoting a highly favourable landscape for clinical research, it shows that the UK can deliver clinical trial excellence that leads the world, particularly for the evaluation of approved therapies. However, for the UK to be a go-to destination for clinical trial research for pre-approved or investigational molecules, other drivers besides research quality need to be understood, for example clinical trial activity. Our results show that in terms of Phase 3 clinical trial activity the UK is comparable to Italy, but lags Germany and France, a gap that is wider when Phase 2 trials are considered. From a European perspective Germany remains the country with numerically the most experience in orchestrating Phase 2 and 3 clinical trials – a total of 635 trials compared with the UK at 522 trials. This analysis cannot intimate reasons for Germany's excellence in clinical trial implementation but given that the ethical frameworks for Germany and the UK are comparable, possible explanations include a large haemato-oncology patient population as well as good trial infrastructure leading to fast start up of clinical trials and high post-trial market potential. Similarly, the regulatory environment in Germany via the Arzneimittelmarkt-Neuordnungsgesetz (Pharmaceuticals Market Reorganisation Act [AMNOG]) procedure encourages collaboration on research to help support pricing of drugs.

The UK demonstrates through this analysis that clinical trials when started are more likely to be completed and when completed to translate into highly robust publications and patent applications. In Phase 1 studies, the UK is leader across the board, and in haematological cancers only second to France. Given the excellence in early Phase clinical trials in the UK, there is a need to explore how improvements in later Phase 2 and 3 clinical trials can be achieved to increase the number of trials undertaken that can be completed and translated

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

into strong citable communicable data that sets the UK apart as a place for researchers, academic trial funding and pharma opportunity. Phase 3 clinical trials are the point where patients can directly access and benefit from medications for their cancer. Options that might be considered to improve the proportion of Phase 3 studies undertaken in the UK include shortening of regulatory timeframes and financial competitive advantages. The UK was shown to be the slowest at 186 days for the regulatory process, which will impact the consideration of the UK as a country of interest. Optimising this timeframe needs to be considered, likely at a governmental level, to bring approvals in line with other countries such as Germany and the US, particularly in a post-Brexit era where access to the centralised approvals system through the European Medicines Agency (EMA) is no longer available. Similarly, there is a need to streamline CTA and ethics procedures. This process is underway through collaboration of the Medical Health Regulatory Agency (MHRA) with the National Institute for Health Research (NIHR) to combine procedures of Clinical Trials of Investigational Medical Products and Clinical Trial Authorisation and Research Ethics Committee opinion. This will comprise the largest overhaul of trial regulation for several decades and accompanies a UK Government commitment to increase clinical trial investment from approximately £9 billion in 2017 the timing of this analysis to £22 billion by 2026–2027. Such a combined way of working may improve approval times. Delays in trial startups are linked to substantial study delays and costs which can threaten the feasibility of a trial, delay access to treatment for patients and lead to lost opportunity costs. [21,22] But, this may require digital transformation and support of digital capabilities, as it is clear that biopharma excellence and digital excellence may not track together. [23] With a median trial set up time for the UK of 6 months, double that of Germany, success of this initiative is a priority. There is a case for central incentivisation of clinical trials in the UK, as happens in the US, that is strategically applied to centres of excellence providing innovation. [24] The joint MHRA and NIHR approach may already be providing benefits with a reduction in clinical trial start up times already reported. Embracing the increasing patient centricity of clinical trials through use of the NHS may provide the UK with a competitive advantage in clinical trial design and recruitment without compromising on time to trial implementation.

Re-invigorating the clinical trial landscape in the UK – particularly following Brexit, the pandemic and an economic downturn – is essential for the fiscal benefits it brings and the benefits to patients in accessing innovative medications. The NHS as a national structure provides multiple centres of excellence and Clinical Research Networks that are highly respected worldwide. However, the NHS continues to operate under increasing burdens, including insufficient funding, patient waiting lists, staff shortages, an aging population and

BMJ Open

However, both the UK and Europe lag the USA in terms of clinical trial investment and countries such as China are increasingly emerging as attractive locations for studies. [25] A connected, less siloed, approach to clinical trial implementation within the UK alone and within the broader context of Europe is required.

Limitations

There are several limitations to these data. From observed data it has been inferred that the UK may be a less attractive country for clinical trials than others in Europe, however nuances to this observation have not been evaluated. It may be that a subjective analysis of pharmaceutical companies and clinical research organisations, perhaps by survey, might provide a different or deeper insight into why the UK up to 2017 was seemingly a more difficult country to navigate for late phase clinical studies. The outcomes we observed suggested that perhaps regulatory hurdles were proving to be barriers to later phase clinical trials, but the impact of a centralised approval structure in the UK has not been evaluated. It may be that current constraints faced by the NHS may, in part, render clinical development in the UK less attractive. This would be an interesting topic for further study. It is possible that limitations of infrastructure may be a contributing factor to the high number of sites recruited for clinical studies which never recruit patients.

The data in this study provide insight into haematological cancer clinical trials up to and including 2017. The data cut-off of 2017 is a challenge; however, these data do allow us to fully understand the UK's capability without the significant uncertainty of the Brexit vote and subsequent COVID-19 pandemic. It would be useful to explore the impact of the UK of both these events since this research. Whilst the data obtained reflects the situation in the UK up to, and including 2017, the situation in the UK, post-Brexit and post-pandemic cannot be known. Given the lifecycle of clinical trials is approximately 10 years, it would be interesting to explore the UK's position with respect to clinical trials in 2027 or beyond. At this timepoint the landscape should reflect a normalcy following Brexit, be relieved of any masking of effect by the COVID-19 pandemic and reflect more clearly the Government initiatives currently in place, which are beginning to provide benefits which we hope will be continued by the new UK Government. Other limitations not explored in this analysis include cost of developing and implementing clinical trials in the UK and other countries, and the potential for Governmental incentives to improve attractiveness. Understanding the role of geographical

location for clinical trials requires an analysis of willingness of countries to invest in clinical studies, their landscape of current healthcare funding, clinical trial capacity from the perspective of the potential patient population and the willingness of patients to be involved in research and would be of interest for future study.

Conclusions

Based on 2017 data the UK lags other European countries as a hub for clinical trial development and implementation. The UK however, when it does undertake clinical trials, clearly provides data that are meaningful and relevant and ultimately useful to drug development and future patient care. As the post-Brexit, post-pandemic landscape shifts in the UK, it may be that future data would show an increase in the volume and impact of clinical development in the UK. Since the pandemic the UK Government proposed to improve the UK as a clinical trials hub. Its response has been to explore the role of telemedicine in trials, the definition of a 'trial' site, and to revise ways of working in line with recommendations from the Taskforce for Innovation, Growth and Regulatory Reform (TIGRR) including ICH E6 guidance on good clinical practice and the development of an Innovative Licensing and Access Pathway (ILAP). In this way effective and efficient pathways to bring innovative medicines to patients earlier should be possible with the UK as a hub for clinical trials. [23]

Acknowledgements

Writing assistance and editorial support was provided by Susan Allen, Brandfish Limited UK and funded by Amryt Pharmaceuticals. The analysis was conducted as part of a successfully defended and awarded MSc thesis from King's College London, by MA funded by Celgene and Amryt Pharmaceuticals.

Authors' contributions

Meena Arora (MA) is the guarantor

MA was responsible for developing and critiquing the survey, data collation and data preparation, data analysis and interpretation, developing the concept and outline of the manuscript and writing, reviewing and revising the manuscript.

JB was responsible for critiquing the survey, data interpretation, developing writing, reviewing and revising the manuscript.

AeB was responsible for critiquing the survey, data interpretation, developing writing, reviewing and revising the manuscript.

AK JB was responsible for critiquing the survey, data interpretation, developing writing, reviewing and revising the manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors

Competing interests

The authors declare there are no current conflicts of interest. MA, JB and AK were employees of Celgene during the time the analysis was conducted. The analysis was conducted as part of research for a successfully defended MSc thesis for MA, which was funded by Celgene and Amryt Pharmaceuticals.

Consent for publication

All authors agree to the publication of this manuscript.

Ethics Approval Not applicable

Figure 1. overview and proportion of GDP spend on healthcare by capita across study countries

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. Data was not available for Spain when the search was conducted, and subsequently checked in 2022.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Figure 2. a) number of active haematological cancer trials in study countries; b) documented number of clinical trials by phase by country; c) completion of clinical trials by phase by country

Figure 3. a) clinical trial performance metrics by countries evaluated; b) maximum expected approval times for clinical trial applications and ethics approvals

References

- 1. Wouters, O.J., M. McKee, and J. Luyten, *Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.* J Am Med Assoc, 2020. **323**(9): p. 844–853.
- 2. FADOI. *The value of independent clinical research in Italy.* Edra Roche Foundation 2019. Available from: <u>https://www.fondazioneroche.it/</u> accessed July 2024
- 3. Polignano M.G., *Economic impact of industry-sponsored clinical trials in inflammatory bowel disease: results from th enational institute of gastroenterology "Saverio de Bellis".* Front Pharmacol, 2022; **13**: 1027760.
- 4. Walter, E., et al., *Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.* J Med Econ, 2020. **23**(6): p. 566–574.
- 5. Tran, D.T., et al., *The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.* Journal of Pharmacy & Pharmaceutical Sciences, 2018. **20**(1): p. 407–414.
- 6. UK Government, House of Commons Health and Social Care Committee. *Cancer Services, Twelfth Report of Session 2021–22.* 2022. Available from: <u>https://committees.parliament.uk/publications/9562/documents/161967/default/</u> accessed January 2024.
- Association of British Pharmaceutical Industries (ABPI). Clinical research in the UK, an opportunity for growth. 2021. Available from: <u>https://www.abpi.org.uk/publications/clinical-research-in-the-uk-an-opportunity-for-</u> growth/ accessed July 2024.
- 8. Medicines and Healthcare Products Regulatory Agency (MedRegs). *The past, the present and the future of clinical trials transparency in the UK.* 2021. Available from: <u>https://medregs.blog.gov.uk/2021/12/22/the-past-the-present-and-the-future-of-clinical-trials-transparency-in-the-uk/</u> accessed July 2024.
- 9. UK Government. Department of Health and Social Care. *The future of clinical research delivery: 2022 to 2025 implementation plan.* Available from: https://www.gov.uk/government/publications/the-future-of-uk-clinical-research-delivery-2022-to-2025-implementation-plan accessed July 2024
- 10. Mullard, A. Shifts in the clinical trial landscape. *Nat Rev Drug Discov*, 2024; **23**: p.239.
- 11. IQVIA Institute. *Global trends in R&D 2024: activity, productivity and enablers. Annual trend report from the IQVIA Institute for Human Data Science.* Available from: <u>https://www.iqvia.com/insights/the-iqvia-institute/reports-and-</u> <u>publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers.</u> Accessed: July 2024.
- 12. Bhatt A. *New clinical trial rules: academic trials and tribulations.* Perspect Clin Res 2019; **10**(3): p. 103–105.
- 13. Blüme A, et al. Investigator initiatied trials versus industry sponsored trials translaltion of randomised controlled trials into clinical practice (IMPACT). BMC Med Res Methodol 2021; **21**: p. 182

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

1 2 3

4

5

6

7

8

9

10

11

12

13

14

15 16

17 18

19

20

21

22 23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

World Health Organization (WHO) Number of aliginal trial registration by location
disease phase of development are and sex of trial participants (1000, 2021), 2021
Available from: https://www.who.int/observatories/global-observatory-on-bealth-
research_and_development/monitoring/number_of_trial_registrations_by_year_location_
disease and phase of development accessed July 2024
Eundytus A et al. Industry Eunding of Oncology Randomised Controlled Trials:
Implications for Design Results and Interpretation Clin Oncol 2022: 34 (1): n. 28–35
Canone G et al. Accelerating clinical trails in the EU (Δ CT EU): transforming the EU
clinical trials landscape. Nat Rev Drug Discov, 2024 doi: 10.1038/d41573-024-00085-
5 Inublished Online First: 202405231
Jefferson L et al No difference found in time to publication by statistical
significance of trial results: a methodological review JRSM Open 2016. 7(10): p
2054270416649283
Mongin, D., Time to publication and time-lage publication bias for randomized trials
on connective tissue disease. ACR Open Rheumatology. 2023; 5(8); p. 420–25.
Pessosa-Amorim, G., Clinical trial results in context: comparison of baseline
characteristics and outcomes of 38.510 RECOVERY trial participant versus a
reference populartion of 346,271 patients hospitalised with COVID-19 in England.
Trials, 2024. 25 (1): p. 429.
Carthon, BC., et al., The STAMPEDE trial: paradigm-changing data through
innovative trial design. Transl Cancer Res, 2016. 5(Suppl 3): p. S485–S490.
Atassi, N., et al., Analysis of start-up, retention, and adherence in ALS clinical trials.
Neurology, 2013. 81(15): p. 1350–5.
Kantarjian, H., D.J. Stewart, and L. Zwelling, Cancer research in the United States:
<i>Dying by a thousand paper cuts.</i> Cancer, 2013. 119 (21): p. 3742–3745.
IMD World Digital Competitiveness Centre. World digital competitiveness ranking
2022. 2022. Available from: https://www.imd.org/centers/world-competitiveness-
<u>center/rankings/world-digital-competitiveness/</u> accessed July 2024.
European Federation of Pharmaceutical industries and Associations (EFPIA).
Factors affecting the location of bipnarmaceutical investments and implications for
bttps://www.ofpia.au/modio/676752/org.ofpia.investment legation final report off
accessed July 2024
Medicines and Healthcare Regulatory Agency (MHRA) Inspectorate, Regulators'
experience of clinical trials during the COVID-19 pandemic (Part 3) – looking forward
2022 Available from: https://mbrainspectorate.blog.gov.uk/2022/02/18/regulators-
experience-of-clinical-trials-during-the-covid-19-pandemic-part-3-looking-forward/
accessed July 2024.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



	Population	GDP per	Annual GDP	GDP spent	Mean
	(Million)	capita	projected	on	expenditure
		(US\$ per	growth rate (%)	healthcare	per capita
		capita)		(%)	(US \$)
USA	313.1	54,640	2.8	7.9	4,317
UK	62.6	32,225	2.3	7.3	2,352
France	63.8	38,870	1.7	8.6	3,343
Germany	82.1	44,985	2.3	8.4	3,779
Italy	60.7	35,067	1.5	6.8	2,385
Spain	46.6	33,720	2.8	8.9*	3,001*

Data from OECD (The Organisation for Economic Co-operation and Development) 2017 country summaries. *Data was not available for Spain when the search was conducted, and subsequently checked in 2022.



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Fig 3

а

1	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
14	
15	
16	
17	
18	
19	
20	
20	
21	
22	
23	
24	
25	
26	
20	
27	
28	
29	
30	
31	
32	
22	
24	
34	
35	
36	
37	
38	
39	
10	
40	
41	
42	
43	
44	
45	
46	
-0 17	
4/	
48	
49	
50	
51	
52	
52	
C	
54	
55	
56	

	Country	Median start up duration (Days)	Median enrolment rate (Patients site / month)	Proportion of non-enrolling sites (%)
	USA	111	0.5	15.9
	UK	186	0.4	27.9
Haematological	France	141	0.6	18.7
cancers	Germany	92	0.6	25.9
	Italy	122	0.5	6.5
	Spain	195	0.6	16.2



Maximum expected CTA approval Maximum expected site ethics approval